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ABSTRACT 
 
The application of Baylis-Hillman methodology has afforded access to a range of β-
hydroxypropionate ester-AZT conjugates as potential dual-action HIV-1 IN/RT inhibitors. Two 
families comprising a total of nine β-hydroxypropionate ester-AZT conjugates were synthesised. 
The first family was accessed using O-benzylated salicylaldehydes and methyl acrylate and the 
second from unprotected salicylaldehydes using tert-butyl acrylate as the activated alkene. 
Spectroscopic methods were employed to fully characterize the compounds. Propargylation of 
the respective Baylis-Hillman adducts was achieved via conjugate addition of propargylamine. 
The resulting products were then employed in Cu(I)-catalysed “click” reactions with 
azidothymidine (AZT) to yield the desired β-hydroxypropionate ester-AZT conjugates. 
Exploratory studies were also conducted to access 4-hydroxycoumarins from Baylis-Hillman 
derived adducts and to construct customized chiral Baylis-Hillman reaction sites. Many 4-
hydroxycoumarins are known to exhibit a wide range of biological activities, and extending 
Baylis-Hillman methodology to access these systems is an important challenge. Two approaches 
were investigated. The first involved the formation of a 4-phthalimidocoumarin, aromatisation 
and hydrolysis of which was expected to lead to the 4-hydroxycoumarin target. The second, a 
variation of the first, involved the use of 4-(chrolomethyl)coumarin intermediates. Unfortunately, 
while various intermediates were prepared and characterised, neither approach led ultimately to 
the desired targets. N-substituted borneol-10-sulfonamides were constructed from camphor-10-
sulfonyl chloride as chiral Baylis-Hillman reaction sites. In a preliminary study, however, none 
of the N-substituted borneol-10-sulfonamides exhibited Baylis-Hillman catalytic activity. 
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1. INTRODUCTION 
 
1.1. THE BAYLIS─HILLMAN REACTION 
The formation of carbon-carbon bonds and functional group transformations constitute important 
challenges in organic chemistry research.1,2 The Baylis-Hillman reaction is one of the recent 
carbon-carbon bond formation reactions and stands alongside other important reactions which 
include the Claisen rearrangements, Friedel-Crafts reaction, Diels-Alder reaction, Aldol reaction, 
Heck reaction and Reformatsky reaction.1 Atom economy is a desirable feature in carbon-carbon 
forming reactions and is achieved in the Baylis-Hillman, Michael, Aldol and Diels-Alder 
reactions.3 An efficient synthetic reaction needs to be not only atom economic but also when 
necessary, permit selective (regio-, stereo- and chemo-selective) transformations and efficient 
catalytic options.1 The Baylis-Hillman reaction, while having both atom economy and functional 
group generation as its features, also has other desirable features, such as organocatalytic and 
aqueous media possibilities both of which are of environmental importance (green chemistry).1,3 
The Baylis-Hillman methodology is also attractive because the starting materials are often 
commercially available, large scale production is feasible, and the reaction proceeds under mild 
conditions.2 
The methodology had its origins in work by different scientists in the sixties and seventies. In 
1963 researchers2,4 reported the tryalkylphosphine-catalysed dimerization of alkyl acrylates to 
give 2-methyleneglutarate derivatives,  and this was followed in 1968 by the description by 
Morita and co-workers4 of the reaction of aldehydes with  acrylates or acrylonitrile using the 
catalyst tricyclohexylphosphine to produce 2-methylene-3-hydroxy alkanoates or alkylnitriles 
(using acrylonitrile). Baylis and Hillman in 1972 reported the production of highly functionalised 
molecules from the coupling of activated alkenes, α,β-unsaturated esters and ketones catalysed 
by tertiary amines, such as quinuclidine and 1,4-diazabicyclo[2.2.2]octane (DABCO) (Figure 1). 
The reaction came to be referred to as the Baylis-Hillman reaction and, subsequently, in 
recognition of Morita’s contribution, also became known as the Morita-Baylis-Hillman (MBH) 
reaction.2,4,5 
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Figure 1. The Baylis-Hillman reaction, as identified in the original patent information.5 
According to Wei and Shi the classical MBH reaction involves the formation of α-methylene-β-
hydroxycarbonyl compounds by the combination of α,β-unsaturated carbonyl compounds with 
aldehydes under the influence of tertiary amine or phosphine as a catalyst.2 It can be described as 
an atom-economic, carbon-carbon bond-forming reaction between activated alkenes at their α- 
position and carbon electrophiles in the presence of a catalyst or catalytic system to produce 
densely functionalized molecules referred to as Baylis-Hillman adducts.3  
The main features of this reaction can be described as follows, first, it has three components 
(electrophiles, activated alkenes or alkynes, and catalysts) enabling a wide selection of 
substrates. When electrophiles are prochiral, a stereogenic centre is generated thus providing the 
asymmetric version of the reaction. The densely functionalised products (MBH adducts), which 
have three functional groups in close proximity to each other, are very useful synthons in the 
construction of various synthetic targets which include natural products. Intramolecular 
elaboration of the adducts can afford heterocyclic and carbocyclic compounds.3-5 Interest in the 
reaction initially grew slowly only to grow exponentially in recent decades as its synthetic 
potential drew the attention of many synthetic organic chemists. In the process, the breadth of the 
three essential elements used in the reaction, viz., the activated olefin, catalyst and electrophile 
has also grown significantly.6 The numerous publications on various aspects of the reaction are 
testimony to its phenomenal growth in recent years.3 
 
1 2 3
4 5 6 
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1.1.1. Activated alkenes/alkynes, electrophiles and catalysts 
Variations in the selection of the essential components, alkyne/alkene, electrophile and catalytic 
system has resulted in the generation of a large number of classes of highly functionalised 
adducts and the lure to create new classes of multi-functionalised molecules is driving research 
in this area.4 Examples of alkenes and alkynes that have been used with success in the Baylis-
Hillman methodology are illustrated in Figure 2. 
 
R = H, Alkyl, Vinyl, Aryl   X = Halide 
Figure 2. Activated, alkenes and alkynes used in the MBH reaction.3,5 
Over the years a number of electrophiles have been used successfully including those illustrated 
in Figure 3. 
 
R = H, Aryl, Alkyl   X = H, Halide, NO2 
EWG = CN, COOR, SO2Ph, COR 
Figure 3. Elecrophiles used in the MBH reaction.3,5 
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Various catalysts have been employed in the Baylis-Hillman methodology with the prominent 
catalysts of choice being DABCO, 3-hydroxyquinuclidine and quinuclidine. Figure 4 shows 
some molecules that have been used as catalysts.1,5,7 
 
 
Figure 4 Catalysts used in the MBH reaction.1,5,7 
 
1.1.2. Accelerating the Baylis-Hillman reaction 
The Baylis-Hillman reaction however faces several drawbacks among which are slow reaction 
rate, low product yield, high concentration of the catalyst and the use of organic solvents that are 
hazardous.8 The reaction may take days or weeks to reach completion, depending on reactivities 
of substrates used. However, its synthetic potential has stimulated investigations into 
modifications of the experimental protocols to mitigate the challenges and thus enhance the 
reaction rate and the yield of the Baylis-Hillman adducts.6,8 Reported modifications include the 
use of more reactive activated  olefins and electrophiles, new catalysts or catalytic systems,  the 
use of excess catalyst, conducting the reaction under high pressure, the use of ultra sound, 
different solvent media, microwave irradiation, mechanical agitation.1,6 Attention has been also 
given to facilitating intramolecular hydrogen bonding through having a hydroxyl group in the 
23  24 25
26  27 28
29  30 31
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substrate or catalyst, variations in the stoichiometry of the reactants and catalyst, additives and 
use of heterobimetallic complexes.1,6,8,9 Most of the refinements, although helpful in increasing 
product yield and the reaction rate are limited to particular substrates.8 The strategies which can 
be divided into chemical and physical methods with the former being more preferable as no 
specialised equipment is required.10  
A solvent free method for rate acceleration and yield increase was developed by Saikia and 
Sarma.6 Equimolar quantities of olefin and aldehyde were reacted in the presence of the catalyst, 
DABCO, at 20 mol% under neat conditions to afford high yields in a short time. They reported 
that their findings give further credence to mechanisms involving proton transfer in aprotic and 
protic solvents. Recently, Aravind and co-workers8 studied the Baylis-Hillman Reaction in a 
PEG-200-DABCO medium under the influence of microwave energy and showed that the 
product yield was enhanced, the reaction time was much shorter and the catalyst concentration 
needed was only one tenth of that needed in a standard Baylis-Hillman reaction. Acke and 
Stevens9 used a micro-reactor for the continuous production of Baylis-Hillman adducts in which 
the rate was approximately 30% faster than under batch conditions with comparable yields. The 
highest yield was achieved using a 1:1:3 molar ratio of 4-nitrobenzaldehyde, DABCO, and 
methyl acrylate in water/1,4-dioxane (1:1 v/v) at room temperature. Aggarwal et al.,10 building 
on the well-reported fact that protic solvents accelerate the Baylis-Hillman used water or small 
amounts of formamide and Yb(OTf)3 as solvent systems. Rate enhancements of up to 120% were 
achieved with methyl acrylate and benzaldehyde using Yb(OTf)3 and formamide.  
Cai and co-workers11 found that the reaction rate of aromatic aldehydes and acrylonitrile or 
methyl acrylate was greatly enhanced in a homogenous water-organic solvent medium; 
moreover, higher yields were achieved at lower temperature. They found that the best catalysts 
were DMAP, DABCO, urotropine and Me3N, while the solvent could be tetrahydrofuran, 
acetonitrile or 1,4-dioxane. In a similar investigation using aqueous-organic solvent systems 
conducted by de Souza et al.,12 it was shown that water and organic solvents mixed at varying 
proportions gave good to high yields in shorter reaction times for certain aromatic aldehydes, 
acrylonitrile and methyl acrylate. The best system for the reaction with methyl acrylate was 
found to be DMSO-water (60:40) and for acrylonitrile, tert-butanol-water (60:40) with 100 % 
mol DABCO as the preferred catalyst. Yields of >98% in 30 minutes in the solvent-free Baylis-
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Hillman reaction of p-nitrobenzaldehyde and methyl acrylate with DABCO as catalyst were 
achieved by Mark and Shumba13 using mechanical agitation, called “high speed ball milling”. 
Shang and co-workers14 developed a new catalytic system, comprising a combination of 
Sc(OTf)3 and 3-hydroxyquinuclidine, that accelerates the Baylis-Hillman reaction. They 
observed that the reaction was best conducted in DMF with 5 mol% of a 1:4 mixture of Sc(OTf)3 
and 3-hydroxyquiniclidine at 40 oC. Using a stoichiometric base catalyst and an aqueous 
medium, Yu and co-workers15 converted a variety of aldehydes (aromatic and aliphatic) to their 
respective Baylis-Hillman adducts while Park and co-workers16 described the use of octanol as 
an additive which greatly accelerated the Baylis-Hillman reaction, enabling the ready conversion 
of reactants into intended products. 1-1-Butyl-2,3-dimethylimidazolium hexafluorophosphate 
([bdmim][PF6]), a new, inert, ionic liquid has also been shown by Hsu and co-workers17 to 
facilitate the Baylis-Hillman reaction with good to excellent yields. 
 
1.1.3. Mechanism 
The wide variety of reactants, catalysts and reaction conditions reported for the Baylis-Hillman 
reactions has presented challenges in the elucidation of the mechanism.3,4 Hoffmann was the first 
to propose a mechanism for the MBH and this was then refined through kinetic studies by Hill 
and Isaacs.18 Bode and Kaye19 undertook NMR-based kinetic studies which supported this 
mechanism, which is illustrated for the DABCO-catalysed coupling of methyl vinyl ketone 
(MVK) with benzaldehyde in Scheme I (Path A). This mechanism commences with the 
nucleophilic aza-michael addition of DABCO to MVK giving a zwitterionic enolate I which then 
reacts with benzaldehyde in an aldol-type reaction to produce zwitterion II which can undergo 
E2 or E1CB elimination to release DABCO following proton migration to provide the MBH 
adduct.3 The rate determining step was taken to be the addition of enolate to the aldehyde.2 Since 
MVK is highly reactive, a competition reaction may also occur in which a second molecule of 
MVK reacts with the zwitterion enolate I to afford the competition product on release of the 
catalyst (Path B).1-3 
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Scheme 1. Early mechanism proposed for the MBH reaction.1 
 
Santos and co-workers20 used electrospray ionisation mass and tandem mass spectrometry to 
probe the mechanism and successfully intercepted the catalytic cycle; they proposed 
intermediates and managed to characterise them. An achievement which provided evidence for 
the mechanism initially proposed by Isaacs and Hill.18 More recently, in a re-evaluation of the 
MBH reaction mechanism by McQuade and co-workers2 proton-transfer was proposed to be the 
rate determining step. They suggested that the MBH reaction mechanism is second-order with 
respect to aldehyde and that the proton-transfer step involved a six-membered hemi-acetal 
intermediate IV (Scheme 2), produced by reaction of the zwitterion III with a second molecule 
of aldehyde. However, Aggarwal and co-workers2,18 suggested that the reaction was only second 
order in the initial stages before autocatalytic proton-transfer. Scheme 2 details the mechanism 
proposed by McQuade and co-workers.21 As before, an enolate is formed by the attack of 
DABCO on the activated alkene; the enolate then attacks an aldehyde molecule to form the 
second enolate III which then attacks a second aldehyde molecule leading to the formation of the 
hemi-acetal intermediate IV. Proton transfer of the α-hydrogen is considered rate determining 
and is followed by elimination of the catalyst to afford the MBH product. 
I II 
I II 
Competition 
Product 
Path A 
Path B 
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Scheme 2. Later mechanistic proposal for the MBH reaction.21 
Using rate and isotope data, Price and co-workers22 demonstrated that the mechanism which 
involves a hemi-acetal intermediate was general for a wide variety of aryl aldehydes and valid in 
cases where additives, be they nonpolar, nonpolar/protic or polar aprotic, were used. They also 
concluded that the reaction was second-order in aldehyde and first-order in acrylate ester and 
DABCO. Amarante and co-workers18 intercepted and structurally characterized new MBH 
intermediates using electrospray ionisation mass spectrometry and their findings supported the 
recent propositions by the McQuade and Aggarwal teams on the mechanism of the MBH 
reaction.  
Robiette and co-workers23 conducted a computational investigation of the MBH reaction 
mechanism that focused on an amine catalysed coupling of benzaldehyde and methyl acrylate. 
They looked at the mechanism under protic solvent-free conditions and how the mechanism and 
the RDS respond in the presence of alcohols. Their predictions in the absence of protic solvent 
were that deprotonation of the α-position was the rate determining step which occurred via a 
cyclic transition state. In the presence of an alcohol, a slightly lower energy pathway is provided, 
in which the alcohol operates as a shuttle in the transfer of the proton from carbon to oxygen.  
I II 
III IV
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1.2. APPLICATIONS OF THE BAYLIS-HILLMAN METHODOLOGY 
The synthetic utility of the MBH adducts is due to the presence of at least three functional 
groups, viz., allylic, alcohol and ketone. Consequently, MBH adducts have been used as synthons 
in the synthesis of a many important cyclic and acyclic compounds,  including drugs and natural 
products.4,18,23 Cyclic compounds that have been accessed include coumarins, indolizines, 
indoles, indazoles, quinolones, chromones, chromenones, chromenes, naphthalenes and 
pyrazoles.4,19,24 Based on the many chemical transformations of MBH adducts that have been 
reported, Lee and co-workers24 have identified eight categories each of which is characterised by 
a particular key reaction; these categories and examples of the corresponding products are shown 
in Table 1. 
Table 1: Categories of chemical transformations of MBH adducts and corresponding products.24 
Category 
 
Examples of compounds synthesised 
1. Nucleophilic aromatic 
substitution 
 
Naphthalenes, quinolines 
2. Radical cyclisation 
 
Exo-methylene tetrahydropyrans, tetrahyrofurans 
3. Ring-closing metathesis 
 
Pyrroles, cyclopentenes, lactones 
4. Friedel-Crafts 
 
Indene derivatives, 2-arylideneindan-1-ones 
5. Halolactonisation 
 
α-arylidene-γ-butryrolactones, 2,5-hydrofurans 
6. Claisen rearrangement 
 
4-Amino-2-benylideneindan-1-ones,3-benzyledene-3,4-
dihydro-1H-quinoline-2-ones 
7. Aldol condensation 
 
3,4-Dihydro-2H-pyrans, ortho-hydroyacetophenones 
8. Reductive cyclisation 
 
γ-Lactams, quinolones, quinolines 
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1.2.1. Bioactive molecules 
Mehta and co-workers25 reported a methodology which they used to access furofuranones, a 
class of compounds from MBH adducts, which were propargylated, converted to γ-butenolides 
and then into the targeted furo[3,2-b]furanones by an oxy-Michael addition reaction. These 
compounds exhibited bioactivity. Five important insect pheromones, (2E,4S)-2,4-dimethylhex-2-
enoic acid, (+)-(S)-normanicone, (+)-(S)-manicone, (+)-dominicalure-I and (+)-dominicalure-II 
were synthesised  by Das and co-workers.26 from MBH adducts by application of stereoselective 
synthesis of trisubstituted olefins. While Junior and co-workers27 synthesised over twenty 
antiparasitic MBH adducts using microwave irradiation. A diastereoselective approach was 
employed by Paioti and Coelho28 for the total synthesis of the highly bioactive styryl lactones, 
(+/-)-leiocarpin A and (+/-)-goniodiol from a common intermediate that was accessed from a 
MBH adduct. Narender and co-wokers29 synthesised six novel MBH adducts from substituted 2-
chloronicotinaldehydes, which they screened for antimalarial activity and half of them were 
found to have substantial activity. 
Novel highly functionalised MBH adducts of artemisinin, a well-known antimalarial agent were 
synthesised from 10-deoxoartemisinin aldehyde and tested for anticancer activity by Goswami 
and co-workers.30 The artemisinin MBH adducts proved to be highly potent against cancer. 
Twenty 3-hydroxy-2-methylene-3-phenylpropionic acid MBH adducts were synthesised and 
tested for antimicrobial activity by Singh and Bhat.31 Most of the derivatives showed potent 
antifungal and antibacterial activities. According to Limar and Vasconcellos32 some simple MBH 
adducts have become a vital class of bioactive agents showing diverse activities such as 
antichagasic, antitumoral, antimalarial, leismanicidal and molluscicidal properties. Narender and 
co-workers33 synthesised multisubstituted quinolones from MBH adducts obtained from 2-
chloronicotinaldehydes and tested them for antimicrobial activity. They found the molecules to 
have significant antifungal and antibacterial activity, while Bhowmik and Batra34 developed a 
novel MBH-mediated approach to the total synthesis of tamiflu (oseltamivir phosphate), an anti-
influenza agent and to total synthesis of gabaculine, a neurotoxin. 
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1.3. COUMARINS 
Coumarins are a large class of compounds which derive their name from Coumarouna odorata 
Aube (Dipteryx odorata), the Tonka bean, from which coumarin, the simplest member was 
isolated in 1820.35,36 These compounds are benzopyrones – compounds which contain a benzene 
ring fused to a pyrone ring which consist of two groups, the benzo-α-pyrones, to which 
coumarins belong, and the benzo-γ-pyrones (chromones) (Figure 5).36  
 
                                       α-Benzopyrone (coumarin)   γ-Benzopyrone (chromone) 
Figure 5. Chemical structures of benzopyrone subgroups.36 
Depending on the presence or absence of additional moieties, coumarins can be divided into 
simple coumarins, furanocoumarins, pyranocoumarins and pyrone-substituted coumarins.36,37 
The sub-groups and examples of each are shown in Table 2 below. Other classifications 
recognize five groups, the simple, furano- and pyranocoumarins identified in Table 2, together 
with the bis- and triscoumarins and the coumarinolignan.35 Coumarins occur in various plant 
families which include Fabiaceae, Apiaceae, Rutaceae, Solanaceae and Asteraceae, with the 
highest concentrations being found in fruits.36,38 Some coumarins have been found in 
microorganisms, fungi and bacteria.36,39 Toxic fungal natural products, aflatoxins have been 
isolated from Aspergillus species, while bacterial coumarins including coumermycin and 
novobiocin have been isolated from Streptomyces.36 At least 1300 natural coumarins have been 
isolated, the large number arising from the different substitution patterns involving any of the six 
available sites on the coumarin nucleus.40  
 
 
 
 
32 33
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Table 2. Main coumarin subtypes and examples following Lacy and O’ Kennedy.36,37 
 
Classification 
 
 
Examples 
 
Simple 
Hydroxylated, alkoxylated or alkylated on benzene ring 
  
 
7-hydroxycoumarin 4-hyroxycoumarin 
 
 
Furanocoumarins 
5-membered furan ring attached to benzene ring. 
Linear or angular 
 
 
 
Psoralen                      Angelicin 
 
 
Pyranocoumarins 
6-membered ring attached to benzene ring 
Linear or angular 
 
 
Seselin                 Xanthyletin 
 
 
Pyrone-substituted coumarins 
Substitution on pyrone ring, often at C-3 or C-4 
 
 
Warfarin 
 
 
 
1.3.1. Uses of coumarins 
Coumarins have diverse uses which range from medicinal to non–medicinal. Non–medicinal 
uses include the following, fluorescent dyes,41 sun-screens, fluorescence indicators, laser dyes,42 
probes in non-biochemical heterogeneous inclusion systems, biochemical and biological 
systems,43 electro-optical applications (in liquid crystalline polymers and in light and energy 
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harvesting and photo-active surfaces), fluorescent tags and in chiral stationary phases for 
HPLC44, additives in perfumes, food and agrochemicals,  and as intermediates in the synthesis of 
compounds such as chromones, fluorocoumarins and coumarones.45,46 Coumarins also exhibit a 
wide spectrum of biological activities including anticoagulant, anthelmintic, anti-HIV, 
insecticidal, antimicrobial, anticancer, anti-inflammatory,13 antioxidant, hepatoprotective, 
antiallergic, antiviral, and antithrombotics.45-49 Pharmacological activities observed for various 
coumarins are shown in Table 3. 
Table 3. Pharmacological activities of various coumarins. 
Pharmacological 
activity 
Coumarin(s) 
1. Anticoagulant Dicoumarol,37 warfarin36
2. Antibacterial Ammoresinol, novobiocin,49 clorobiocin36 
3. Anti-inflammatory Coumarin, scoparone,40 esculetin49 
4. Antioxidant Esculetin,49 Umbelliferone,  herniarin39 
5. Anticancer Scoparone,39 esculetin,36 osthole49 
6. Antifungal Osthole, psoralen49
7. Antihypertensive Scoparone,39 scopoletin49 
8. Anti-HIV-1 Calanolide A and B,48 michellamine B50 
9. Immunostimulatory Coumarin, 7-hdroxycoumarin51 
 
 
1.3.2. Synthesis of coumarins 
The many applications of coumarins have made them attractive targets. Classical syntheses, such 
as the Pechmann, Wittig, Perkin, Knoevenagel, Reformatsky, Raschig and Claisen 
reactions,45,46,52,53 have various drawbacks, including extreme reaction conditions, expensive 
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catalysts and waste challenges.53,54 New approaches which address some of these challenges and 
which involve greener protocols have been developed.45,53,55  
Perkin reaction 
The Perkin condensation is perhaps, the simplest protocol for the synthesis of substituted 
coumarins.56 The reaction was first reported by Perkin,57 and involved heating salicylaldehyde 
with acetic anhydride and anhydrous sodium acetate (Scheme 3). 
 
 
Scheme 3. The Perkin reaction.35,57 
More generally, the Perkin synthesis can be described as the formation of coumarins by an aldol 
condensation of acid anhydrides and ortho-hydroxybenzaldehyde in the presence of an alkali salt 
of the acid.35 The protocol has a narrow substrate scope and improvements have been reported 
involving use of anhydrous sodium fluoride as catalyst, use of a Mukaiyama esterification 
protocol and the mediation by propylphosphonic anhydride (T3P) acid.35,56 
Pechmann Reaction 
The Pechmann reaction, also known as the Pechmann condensation, is the most widely used 
method in the synthesis of coumarins due to its use of simple starting materials, viz., β-ketoesters 
and phenols.58,59 In the original reaction, Pechmann57 synthesised a coumarin derivative by 
heating a mixture of phenol, malic acid and sulphuric acid.  Generally, the reaction involves the 
condensation of phenols and β-ketoesters catalysed by acids (Scheme 4)35 and can be considered 
to occur through three steps,60 hydoxylalkylation, transesterification and dehydration. Acids such 
as H2SO4, HCl, POCl3 and P2O5 have been reported as catalysts and have been used in large 
molar excess e.g. 5-fold for phosphorus pentoxide and 10-12-fold for sulphuric acid.61 Use of 
excess acid catalyst is not environmentally attractive,60 and the use of Amberlyst-15, Fitrol, 
Nafion resin/silica nanocomposites and H-BEA has been reported as improved alternatives.35,60 
34  32
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Scheme 4. The Pechmann reaction.35 
Romanelli and co-workers59 have synthesised coumarins by the Pechmann reaction using a 
Wells-Dawson heteropolyacid as a catalyst in a solvent-less protocol. The catalyst could be used 
again with no change in yields. Maheswara and co-workers61 synthesised substituted coumarins 
in a Pechmann reaction invoving a heterogenous recyclable catalyst (HClO4.SiO2) in a solvent-
free protocol. Other improvements to the Pechmann synthesis are use of Zeolite catalyst,62 
microwave assisted solvent-free synthesis63 catalysed by ZrOCl2.8H2O, catalysis by 3-methyl-1-
sulphonic acid, an imidazolium sulphate halogen-free recyclable acidic ionic liquid58. The use of 
titanium(IV) chloride under solvent-free conditions which was reported by Valizadeh and 
Shockravi64 to afford products in higher yields than those obtained under standard conditions.  
Knoevenagel Reaction 
The condensation of aldehydes and active methylene compounds in the presence of amines or 
ammonia is known as the Knoevenagel reaction.35 KnoevenageI first reported the solution phase 
synthesis of coumarins by the condensation of malonic acid with ortho-hydroxarylaldehydes in 
1898, as illustrated in Scheme 5. 
 
 
Scheme 5. The Knoevenagel reaction. 35 
35  36
34  37 32 
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Phadtare and Shankarling66 reported a protocol aimed at making the reaction greener. They 
synthesised coumarins using a biodegradable catalyst, choline chloride, in aqueous media and the 
catalyst could be reused several times without decrease in yield or activity. Prajapati and 
Gohain67 used molecular iodine as a catalyst in a microwave irradiated version of the 
Knoevenagel condensation, obtaining coumarins in high yields. 
Reformatsky reaction  
The reaction involves the condensation of ketones or aldehydes with organozinc compounds of 
α-halo esters yielding β-hydroxyesters, which undergo lactonisation to coumarins under 
appropriate conditions (Scheme 6).35 
 
 
Scheme 6. The Reformatsky reaction.35 
Improvements to the classic method have included the use of tellurium–triggered cyclisations 
and use of ultra sound.68 Other less conventional methods have been developed for the synthesis 
of coumarins, e.g., the stereo- and regioselective palladium-catalysed hydroarylation of 
functionalised alkynes with aryl halides (Scheme 7).35 Van and co-workers45 used ring-closing 
metathesis with Grubbs catalyst to synthesise coumarins from phenols while Gao and co-
workers69 reported a one-pot microwave assisted synthesis of coumarins under solvent-free 
conditions, using Meldrum’s acid, phenol and Eaton’s reagent. 
 
38  39
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Scheme 7. Palladium-catalysed synthesis of coumarins.35 
 
1.3.3. 4-Hydroxycoumarins 
There has been a great deal of interest in 4-hydroxycoumarins (2H-1-benzopyran-2-ones) arising 
from their photodynamic and numerous pharmacological activities, which include: anti-
inflammatory, anti-arthritic, antibacterial, anti-cancer, anti-coagulant and anti-viral.70,71 The 
discovery of  dicoumarol as the agent responsible for a haemorrhagic disease in cattle fed on 
sweet clover hay, that had begun to ferment, stimulated the study of 4-hydroxycoumarins and led 
to the development of warfarin (Figure 6), as a rodenticide and of 4-hydroxycoumarin (4-HC) 
analogues as therapeutics for thromboses, rheumatic heart defects, embolisms, stenocardia, 
angina, myocardial infarcts and thrombophlebitis.72,73,74 Typified by warfarin which was 
introduced into clinical practice more than 50 years ago, 4-hydroxycoumarins have become the 
mainstay of oral anticoagulant therapy for various thromboembolic health conditions.75 These 
compounds are antagonists of vitamin K and target vitamin K epoxide reductase, inhibiting its 
reduction to dihydrovitamin K and resulting in the regulation of blood coagulation.70,72 The 4-
hydroxycoumarin anticoagulants have in common an enolic benzopyran structure (Figure 6) 
which appears to be a requirement for vitamin K.75 
 
42  43 44 
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Figure 6. 4-Hydroxycoumarin coagulants.70,75 
Derivatives of 4-hydroxycoumarin have also provided alternative non-catechol-containing HIV-1 
integrase inhibitors of high inhibitory potency, examples of which are coumermycin and the 
tetrameric compound shown in Figure 7.76 Mazumder and co-workers77 investigated the latter 
compound and found it to show anti-viral, anti-integrase and anti-protease activity. A number of 
other synthetic approaches to 4-hydroxycoumarin derivatives been reported in literature. 
Danchev and co-workers,70 for example, condensed of 4-hydroxycoumarin with substituted 
aromatic aldehydes or unsaturated ketones (Scheme 8). 
 
 
Figure 7. Tetramer NSC 158393.76,77 
45  46
47  48
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R = H, Halogen, Nitro   (a): pyridine, NaOH, EtOH 
Scheme 878 
Swenson’s group79 reported a synthesis of 4-hydroxycoumarin derivatives from benzyl malonic 
acid and phenol. Varying the conditions they were able to synthesise 3-(p-azido-, p-amino- and 
nitobenzyl)-4-hydroxycoumarins. Dezelic and Trkovnik80 used a modified form of the Pauly-
Lockemann method to convert 2-acetoxy-5-bromo-benzoate to 4-hydroxy-6-bromocoumarin. 
 
1.4. HIV-1 ENZYMES INHIBITION 
The human immunodeficiency virus type-1 (HIV-1) has been identified as the causative agent of 
the acquired immunodeficiency syndrome (AIDS).81 Despite the development and discovery of a 
number of chemotherapeutic agents, AIDS remains a significant health-threat worldwide. 
Therapeutic agents of the nucleoside (e.g., AZT, D4T, and DDC) and non-nucleoside HIV 
reverse transcriptase (RT) inhibitors and protease (PR) inhibitors have been used and, at times, in 
combination therapy. However, toxicity and the emergence of drug resistance present serious 
challenges.48 The development of drug resistance is compounded by the HIV’s high rate of 
mutation; hence the need for new drugs with novel structural features and inhibition 
mechanisms.50 Steps in the HIV replicative cycle present themselves as targets for 
chemotherapeutic intervention and these steps include: adsorption of the virus on the host cell 
membrane; fusion of the viral case with host cell membrane; viral nucleocaspid uncoating; 
reverse transcription of viral RNA to proviral DNA; integration of the proviral DNA into the 
cellular genome; replication of DNA; and transcription of proviral DNA to RNA.48  
 
50  51 52
Introduction	
 
20 
 
1.4.1. Reverse Transcriptase Inhibition 
The reverse transcription of genetic material is a critical step unique to retroviruses, of which the 
HIV is one.50 A retrovirus is a single stranded RNA virus which uses DNA polymerase (RT) to 
make double stranded DNA which can insert itself into the host cell DNA. Inhibition of this 
critical step in viral replication offers an attractive target in the treatment of AIDS.82 Nucleoside 
reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) are the two main categories of HIV-1 RT inhibitors, and over 50 structural classes of 
such inhibitors have been described.83  
NRTIs are analogues of deoxynucleosides which lack an OH group on the 3` carbon of the 
deoxyribose moiety but contain a 5`-OH group which can be triphosphorylated by host cell 
kinases thus permitting them to be mistaken by RT as natural nucleotides.84 The NRTIs 
incorporated into the growing viral DNA chain then function as chain terminators.83 In contrast, 
NNRTIs do not need metabolic activation in the host cell and are exemplified by diverse 
hydrophobic molecules whose inhibitory activity depends on interaction with the non-nucleoside 
binding pocket-an allosteric site located 10 Å from the RT DNA polymerase active site.82,84 The 
DNA synthesis is then stopped by the conformational change that results from the binding of the 
inhibitor at the allosteric site. Figures 8 and 9 show some commercially available NRTIs and 
NNRTIs respectively. 
 
 
Figures 8. Some commercially available NRTIs84 and NNRTIs.83 
Natural products with HIV-1 RT inhibitory activity have been found in plants, micro-organisms 
and in marine organisms, while many synthetic compounds have also proved to be active RT 
inhibitors.50  
NRTIs NNRTIs 
53 54  55 56
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1.4.2. Integrase Inhibition 
 HIV-1 integrase (IN), a pivotal enzyme for HIV-1 replication, facilitates insertion of viral DNA 
into the host cell genome.85 The integration process has 3 steps, two of which are catalysed by 
IN, viz., 3`-processing, involving the step-wise removal of two nucleotides from each end of the 
reverse-transcribed viral DNA, followed by strand transfer in which the processed viral DNA is 
inserted into the host DNA.86 The essential role IN plays in HIV-1 replication and its lack of a 
human counterpart have made it a good target for anti-AIDS therapeutics.85,86 In 2007, 
Raltegravir (Figure 9) became the first IN inhibitor to be licenced.81,87 In 2012, elvitegravir 
(Figure 9) became the second IN inhibitor to receive regulatory approval and, like raltegravir, is 
an integrase strand-transfer inhibitor (INSTI).88 
 
                                    Raltegravir                                                        Eltegravir  
Figure 9. The first INSTIs to be approved.81,88 
During the last 20 years, many diverse compounds, including peptides, mononucleotides, 
dinucleotides, oligonucleotides, quinolones, quinolone derivatives and hydroxylated aromatics 
have been reported as IN inhibitors some of which are illustrated in Figure 10.81,89  
 
 
 
Figure 10. Miscellaneous IN inhibitors.89 
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A class of IN inhibitors characterized by the presence aryl β-diketo acid (DKA) moiety (Figure 
11) emerged in the late 1990s, having been discovered independently by scientists from Merk 
and Shionogi research laboratories.90,91 The DKAs specifically inhibit the integration strand-
transfer step and have been reported to be potent HIV-1 IN inhibitors in vitro and in vivo.91 The 
DKA  class of IN inhibitors has shown great promise, and various groups have used the DKA 
template to develop novel IN inhibitors and to explore how the DKA inhibitors function. 90,93  
 
                                  5CITEP92                                                   L-708,90690 
Figure 11. DKA moiety structure and 2 DKA IN inhibitors. 
Burke and co-workers90 used 5ClTEP, 1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-
yl)propenone and L-708,906 as model DKA leads in a structure activity study. Davies and co-
workers92 studied the structure of a complex of the IN core domain with 5ClTEP. A novel class 
of IN inhibitors was discovered by Neamati and co-workers93 through a 3-D pharmacophore-
guided search. They generated a common-feature pharmacophore hypothesis based on 
bioisosteres of β-diketo acid IN inhibitors. The set was made up of 5ClTEP, S-1360 (the first IN 
inhibitor to undergo clinical trials) and two other analogues (Figure 12). 
62  63
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Figure 12. DKA 62 and bioisosteres 64-66.93 
The substitution of the 1,3-DKA moiety by 8-hydroxy- (1,6)naphthyridine resulted in a new 
family of DKA derivatives that are also IN strand-transfer inhibitors, exemplified by the 
naphthyridine compounds L-870,810 and L-870,812 (Figure 13).91  
 
L-870,812                                              L-870,810 
Figure 13. DKA derivatives.91 
The DKA motif consisting of γ-ketone, enolizable α-ketone and carboxylic acid (or heteroaryl 
replacement) has been reported as necessary for the inhibitory activity of the DKAs whose 
common pharmacophore (or bioisostere) is illustrated in Figure 14.94 Shinkai and co-workers94 
noted that the enolizable ketone at the α-postion of the DKAs is replaceable by  a phenolic 
hydroxyl group suggesting that the α-enol form is the biologically active co-planar conformation 
and that the bioisoteres are three functional groups capable of adapting co-planar arrangement 
and mimicking the carboxyl oxygen, γ-ketone and α-enolizable ketone present in the DKA.  
62  64
65  66
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Figure 14. Alignment of DKAs and selected bioisosters,94 illustrating their pharmacophoric 
similarities. 
 
1.4.3. Dual action inhibition of HIV-1 enzymes 
Highly active anti-retroviral therapy (HAART) has been used to lower the viral load in AIDS 
patients and improve their quality of life, but the efficacy of this therapy has been compromised 
by imperfect patient adherence to the complicated dosing, the toxicity of the drugs, viral rebound 
and the emergence of multi-drug resistance.95 Using a single drug to inhibit two viral enzymes at 
the same time could lead to simplified dosing, and thus improved patient adherence, lower 
toxicity and reduced likelihood of drug resistance.96 Morphy and Rankovic97 proposed the 
concept of designing multifunctional ligands. They called ligands with specific multi-target 
roles, “designed multiple ligands (DMLs)” and categorized them as “conjugates”, (for scaffolds 
linked by a linker), “fused”, (directly coupled with no linker) and “merged” (for scaffolds 
integrated in a single structure and sharing common features). Vince and co-workers95 coined the 
69
70 (S1360) 
62 (5ClTEP) 
72
68 (L-870,810) 
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term “portmanteau inhibitor” to describe  the classification of inhibitors in which two scaffolds 
are merged into one but act at different sites in the viral life-cycle. There has been increasing 
recognition that molecules that can target more than one target at the same time can be used to 
treat a number of diseases in contrast with the “one molecule, one target and one disease 
approach” upon which drug discovery has been based until the beginning of the 21st century.98 
Interest in dual or multi-target ligands has also grown due to their generally simple 
pharmarcodynamic and pharmacokinetic properties  in comparison with the combined 
application of several drugs; moreover such ligands often possess improved efficacy.99 
Computer-aided design in drug development has obvious potential as it permits new lead 
compounds to be designed and they are evaluated for potential bioactivity before preparation of 
the compounds and their experimental biological assay.100 Soliman and Moonsamy96 designed 
compounds with potential as dual-action inhibitors against PR and RT. The pharmacophoric 
features of the compounds were based on the known PR and RT inhibitors, Darunavir and 
Zidovudine (Figure 15). Binding affinities of the dual acting compounds were found to be 
comparable to and, in some cases, higher than the reference drugs, with compound 74 (Figure 
16) being the most active against both RT and IN. 
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Figure 15. Darunavir-PR complex and Zidovudine-RT complex used to assign the 
pharmacophoric moieties (reproduced by permission).96 
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Figure 16. Potential dual-action inhibitors based on Darunavir and Zidovudine.96 
Vince and co-workers95 designed bi-functional inhibitors for IN and RT based on 1-[(2-
hydroxyethoxy) methyl]-6-(phenylthio)thymine NNRTIs and DKA IN inhibitors. Biochemical 
studies of the compounds showed significant activity against IN and RT and low cytotoxicity. 
The best compound had an IC50 of 24 nM against RT, 4.4 µM against IN, and 10 nM against the 
HIV-1virus (Figure 17). The minimum requirement for IN binding is a double metal ion 
chelating moiety and a hydrophobic benzyl group; the incorporation of such a moiety into an 
NNRTI scaffold results in a potential IN/RT inhibitor as illustrated in Figure 18.101 
73  74
75  76
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Figure 17. Portmanteu inhibitor based on RT and IN inhibitors.95 
 
Figure 18. A dual IN/RT inhibitor based on incorporation of a hydrophilic chelating moiety in 
the delavirdine scaffold.101 
 
 1.5. CUSTOMISED REACTION SITES 
Nature has influenced the design of a number of inventions, among which is the aeroplane (based 
on the bird), submarine (fish), and microphone (eardrum). Researchers at SFU, British Columbia 
in 2008 developed a technology which uses specialised nano-optics for anti-counterfeiting of 
bank notes which replicates the shimmering iridescence of the Blue Morpho butterfly’s wings 
which is due to reflection and fragmentation of light waves off nano-sized holes on the surfaces 
77 
69  78
79  80
Introduction	
 
29 
 
of the butterfly’s wings.102 The shape of the Shinkansen Bullet train nose was inspired by the 
kingfisher’s ability to dive into water with barely a ripple. The design, a 50 foot steel nose which 
resembles the bird’s beak, resulted in reduced power use and increased speeds.103 Such 
inspiration from nature known as Biomimicry or Biomimetics has resulted in the birth and 
development of Biomimetic Chemistry. Biomimetic Chemistry attempts to mimic natural 
enzymatic processes and reactions in order to improve organic chemistry.104 Biomimetic 
Chemistry takes inspiration not blueprints from natural chemistry.105 
Biochemical reactions are often superior to simple chemical reactions with respect to speed, 
conditions (normally mild conditions) and yield. Enzyme-controlled reactions are 
stereoselective, regioselective, and substrate specific; this among other things enables the 
formation of pure enantiomers from non-chiral precursors-quite attractive aspects to synthetic 
chemists.106 The substrates are bound in well-defined geometries (enzyme-substrate complexes)  
where only certain substrates fit and particular points of the substrate can be attacked, hence the 
resultant substrate-, reaction- and stereoselectivity.106,107,108 The stereocontrol has inspired the 
use of reagent-substrate complexes where a relatively rigid reagent directs attack to a specific 
part of the substrate.106 Endeavours to mimic the attractive aspects of natural enzyme controlled 
reactions have led to the generation of artificial enzymes (catalysis by design),108  customised 
active sites or engineered catalysts. 
Cyclodextrins and recently, calixarenes, have found use in Biomimetic Chemistry especially in 
host-guest chemistry and enzyme mimics.109 Other substances that have been explored in the 
mimicking of functions and structures of natural enzymes include metal complexes, polymers, 
supramolecules, porphyrins, nanozymes (nanomaterial-based artificial enzymes).110 Simple 
cyclodextrins like α-cyclodextrins have been shown to act as catalysts, for example, in the 
chlorination of anisole (Figure 19).111 The binding of anisole in the cavity provides regiocontrol 
leading to selective chlorination in the para position whereas, in the absence of the cyclodextrin, 
ortho and para positions are chlorinated.108,111 The selective catalysis was also accompanied with 
a higher rate of reaction and different kinetics.111 Substrates were also shown to be protected 
from reagents that could not be catalytically delivered by the cyclodextrin groups. 
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Figure 19. Cyclodextrin-catalysed chlorination of anisole.111 
Active sites can also be made using molecular imprinting. In this approach selective binding sites 
are made by using a molecular template.112 The target molecule or its derivative is used as a 
template for imprinting cross-linked polymers. Removal of the template after polymerisation 
exposes binding sites that are complementary in the position of functional groups, size and shape 
then affords a substrate-selective polymer.112,113 The molecular recognition capacity shown by 
the imprinting effect has been attributed to the production of a shape-selective cavity that is 
complementary to the template and the prior-arrangement of functional groups in the polymer by 
the template.114 To organise the functional monomers around the template, interactions such as 
covalent, non-covalent, electrostatic  and metal ion coordination can be used.115 The molecular 
imprinting technology first appeared  80 years ago and the material used then was silica gel.116 
 
1.6. PREVIOUS WORK DONE IN THE GROUP 
The Baylis-Hillman reaction has been applied in our group in the synthesis of various 
heterocyclic compounds, which include chromenes, coumarins, indolizines, quinolones and 
thiochromenes.117 Several approaches have been used to access coumarin derivatives from 
Baylis-Hillman adducts. In one approach O-benzylated 2-hydroxybenzaldehydes are used as 
starting material with methyl acrylate as the activated alkene and cyclisation being achieved 
through either acid catalysis or hydrogenation using Pd-C catalyst (Scheme 9).118 In a more 
direct approach, use of tert-butyl acrylate as the activated alkene,  acid-catalysed cyclisation of 
unprotected Baylis-Hillman adducts affords coumarin derivatives (Scheme 10).119 
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Scheme 9. Coumarin derivatives from protected 2-hydroxybenzaldehydes.118 
 
Scheme 10. Coumarin derivatives from unprotected 2-hydroxybenzaldehydes.119 
Coumarin derivatives, accessed from Baylis-Hillman adducts, have been explored as potential 
dual-action HIV-1 protease and reverse transcriptase inhibitors as part of our research involving 
applications of Baylis-Hillman methodology in the synthesis of more complex molecular 
targets.120 Click chemistry was used to couple azidothymidine, an RT inhibitor, with Baylis-
Hillman-derived coumarin derivatives to access potential HIV-1 PR/RT inhibitors (Scheme 
11).120,121 The conjugates, both N-benzylated and non-benzylated, were evaluated for their HIV-1 
RT and PR inhibition potential using enzyme-inhibition assays, computer modelling and 
saturation difference NMR techniques.121 
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Scheme 11. Synthesis of coumarin-AZT conjugates. 
Cinnamate ester-AZT conjugates have been synthesized from O-benzylated 2-
hydroxybenzaldehydes (Scheme 12),122 while other investigations involving Baylis-Hillman-
derived heterocycles with medicinal potential have included the synthesis of hydroxyethylene 
dipeptide isosteres containing coumarin, chromene, thiochromene and chromone moieties as 
89 95
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analogues of ritonavir, a PR inhibitor.123,124  Research has also focussed on kinetic and 
mechanistic studies of the Baylis-Hillman and related reactions.125,126 
 
Scheme 12. Synthesis of cinnamate ester-AZT conjugates. 
 
1.7. AIMS OF THE CURRENT INVESTIGATION 
The present study continues our emphasis on applications of Baylis-Hillman methodology in 
synthesis and was expected to involve the following objectives: 
1. Synthesis of benzylated and non-benzylated Baylis-Hillman adducts and their use in the 
synthesis of cinnamate esters that are analogous to DKAs as potential dual-action HIV-1 RT/IN 
inhibitors 
2. Synthesis of customised camphor-based Baylis-Hillman reaction sites. 
3. Evaluation of the customised reaction sites as Baylis-Hillman reaction catalysts. 
4. Synthesis of analogues of 4-hydroxycoumarin using Baylis-Hillman methodology. 
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2. RESULTS AND DISCUSSION 
 
This discussion will cover applications of Baylis-Hillman methodology in the synthesis of β-
hydroxypropionate ester-AZT conjugates as potential dual-action HIV-1 IN/RT inhibitors 
(Section 2.1) and in exploratory studies on accessing 4-hydroxycoumarins (Section 2.2) and on 
the construction of customised chiral Baylis-Hillman reaction sites (Section 2.3). Overall 
reaction plans to access the ester-AZT conjugates are shown in Scheme 13. 
 
 
Scheme 13. Reaction plans for β-hydroxy ester-AZT conjugates. 
2.1. SYNTHESIS OF β-HYDROXYPROPIONATE ESTER-AZT CONJUGATES 
AZT is an established RT inhibitor and DKAs are known IN inhibitors as mentioned earlier. β-
hydroxy ester derivatives are analogues of the DKAs and, consequently, may be expected to  
have anti-IN activity. It was hoped that joining AZT and β-hydroxy ester moieties would result 
in the formation of molecules which might act as dual-action inhibitors of HIV-1 RT and IN. 
2.1.1. Synthesis of β-hydroxy ester-AZT conjugates from O-benzylated salicylaldehydes 
The pathway used involved several steps, viz., i) the benzylation of the 2-hydroxybenzaldehydes 
110a-c (Scheme 14); ii) a Baylis-Hillman reaction between each of the O-benzylated 
salicylaldehydes 105a-c and methyl acrylate; iii) conjugate addition of propargylamine to the 
104 105 106 107 
108 109
Results and discussion	
 
35 
 
Baylis-Hillman adducts 106a-c; and, finally, iv) the click reaction of the propargyl derivatives 
111a-c with AZT. Baylis-Hillman reactions of 2-hydroxybenzaldehydes with methyl (or ethyl) 
acrylate are known to result in the spontaneous formation of complex mixtures of 2-chromene 
and coumarin derivatives.118 Benzylation of the 2-hydroxy group, however, permits isolation and 
controlled elaboration of the O-benzylated adducts.118  
 
Scheme 14. Synthesis of β-hydroxypropionate ester-AZT conjugates 107a-c from the O-
benzylated salicylaldehydes 105a-c. 
 
Benzylation was achieved in yields of 65-87% by heating the compounds 110a-c with benzyl 
bromide and NaOH(aq) under reflux for 30 minutes (Table 4). An alternative approach to the 
 
 R1 
a Br 
b Cl 
c H 
110a-c 105a-c 106a-c 
111a-c 97
107a-c 
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benzyl ethers, in which the salicylaldehydes are reacted with benzyl bromide under reflux in the 
presence of K2CO3 and KI for 12 hours, was initially employed but then abandoned due to the 
generally lower yields (the maximum yield achieved with this approach was 54%). The 1H NMR 
spectrum for compound 105a shows the benzylic proton singlet at 5.18 ppm, the aldehydic 
proton singlet at 10.46 ppm and the expected aromatic proton signals between 6.9 and 8.0 ppm 
(Figure 20). In the 13C NMR spectrum, the signals at 70.8 ppm and 188.3 ppm correspond to the 
benzylic and aldehydic carbons, respectively, while the remaining ten signals correspond to the 
aromatic carbons (Figure 21). 
Table 4. Yields of 2-(benzyloxy)benzaldehydes 105a-c.
 
Compound R1 Isolated Yields (%)
105a Br 87 
105b Cl 81 
105c H 65 
 
Figure 21.  400 MHz 1H NMR spectrum of compound 105a in CDCl3. 
 
 CHO 
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Figure 22.  100 MHz 13C NMR spectrum of compound 105a in CDCl3. 
 
2.1.2. Baylis-Hillman reaction of the O-benzylated salicylaldehyde 105a-c with methyl 
acrylate 
The salicylaldehyde benzyl ethers 105a-c were then reacted with methyl acrylate in DABCO-
catalysed Baylis-Hillman reactions with CHCl3 as solvent. The reactions were allowed to run for 
21 days with stirring at room temperature. Work-up afforded the Baylis-Hillman adducts in 
yields ranging from 54 to 64% (Table 5).  The 1H NMR spectrum of methyl 3-(2-benzyloxy-5-
bromophenyl)-3-hydroxy-2-methylenepropanoate 106a (Figure 23) shows the methyl proton 
signal as a singlet at 3.74 ppm, the benzylic protons resonating as a singlet at 5.05 ppm and the 
3-methine proton at 5.89 ppm. The vinylic proton signals appear as singlets at 5.66 ppm and at 
6.30 ppm (characteristic of these protons in Baylis-Hillman adducts, exhibiting no germinal 
coupling). The DEPT 135 NMR spectrum (Figure 24) shows the methyl, 3-methine and benzylic 
 
CHO OCH2
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carbons resonating at 52.0, 67.7 and 70.4 ppm respectively. The methylene signal at 126.5 ppm 
confirms attachment of the two vinylic protons on the same carbon (C-3`). 
Table 5. Yields of methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylenepropanoates 106a-c. 
                                                    
Compound R1 Isolated Yields (%)
106a Br 54 
106b Cl 61 
106c H 64 
 
 
 
 
 
 
 
 
 
 
Figure 23. 400 1H NMR spectrum of compound 106a in CDCl3. 
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Figure 24. DEPT 135 NMR spectrum of compound 106a in CDCl3. 
 
2.1.3. Synthesis of 3`-propargylamino derivatives 111a-c 
The Baylis-Hillman adducts 106a-c were then reacted with propargylamine in dry THF. In each 
case, the reaction mixture was stirred at room temperature for 3 days. The propargyl moiety 
enables the subsequent click reaction with AZT. Flash chromatography following work-up 
afforded the products 111a-c in yields of up to 97% (Table 6). Further purification using 
preparative layer chromatography (PLC) instead of flash chromatography permitted the isolation 
of diastereomers in the cases of the 5-bromophenyl (111a) and the benzyloxyphenyl (111c) 
derivatives. Due to the presence of the stereogenic centres in componds 106a-c, 4 stereoisomeric 
products are expected in each case, i.e. 2 diastereisomeric pairs of enantiomers. The 1H NMR 
spectrum of one of the diastereomeric pairs of enantiomers 111a shows the benzylic proton 
signal at about 5.07 ppm and the methylene proton signals NCH2C and CHCH2 proton signals at 
 
3’-CH2 OCH2
CHOH OCH3 
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about 2.88 and 3.11 ppm respectively (Figure 25). The DEPT 135 NMR spectrum (Figure 26) 
shows the methylene carbons, NCH2C, CHCH2 and OCH2 resonating at 38.2, 48.4 and 71.6 ppm 
respectively. Interestingly the DEPT spectrum also reveals two quaternary carbon signals at 72.4 
and 80.6 ppm which suggests that the quaternary acetylenic carbon also bore a proton. The 
appearance of the quaternary alkyne carbon signal in the DEPT 135 spectrum is, in fact, due to 
the large 2JC,H coupling. 
Table 6. Yields of propargyl amino derivatives a-c. 
R1
O
OOH
O
R1
O
OOH
N
H
O
H2N
THF
Bn Bn  
Compound R1 Isolated Yields (%) 
111a Br 84 
111b Cl 97 
111c H 76 
 
 
Figure 25. 400 MHz 1H NMR spectrum of compound 111a in CD3OD. 
 
OCH3 
OCH2CHOH 
C≡CH 
NCH2C 
CHCH2
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Figure 26. DEPT 135 NMR spectrum of compound 111a in CD3OD. 
 
The diastereomeric ratios (based on the isolated yields) for compounds 111a and 111c were 
56:44 and 60:40, respectively. The relative chemical shifts of the carbon signals for the 
diastereomers of 111a are shown in the corresponding 13C and DEPT 135 spectra (Figures 27 
and 28). The spectra reveal similar signal patterns in each case but the chemical shifts are 
different, confirming the diasteromeric relationship between the isomers.  
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Figure 27. 100 MHz 13C NMR spectra of diastereomers 111a1 and 111a2 in CDCl3. 
 
Figure 28. DEPT 135 NMR spectra of diastereomers 111a1 and 111a2  in CDCl3. 
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2.1.4. Click reaction of propargylamino derivatives 111a-c 
The propargyl derivatives 111a-c were reacted with AZT in CH3CN in the presence of a Cu1 
catalyst and Et3N (Scheme 26). The term ‘click reaction’ or, alternatively, ‘click chemistry’ 
originates from Sharpless and co-workers127 who, inspired by nature’s ability to synthesize from 
small units the three main families of macromolecules (polynucleotides, polypeptides and 
polysaccharides), endeavored to use heteroatom links (C-X-C) to join small units in the 
generation of products and coined the approach ‘click chemistry’. Click chemistry facilitates 
faster drug lead discovery and optimization.128 The click reaction binds two molecular building 
blocks under mild conditions in high-yielding, selective and facile reactions.129 Common 
examples of these C-heteroatom bond-forming reactions include cycloadditions of unsaturated 
species, e.g., 1,3-dipolar cycloaddition and Diels-Alder reactions, nucleophilic substitution and 
additions to C-C multiple bonds, e.g., aziridination and epoxidation.127 
The CuI-catalysed azide/alkyne cycloaddition (CuAAC) is the most widely used click reaction. It 
can be performed using CuI from various sources or CuI pre-catalysts, which include use of a 
CuII salt together with sodium ascorbate as a reducing agent, or a CuI compound such as CuBr 
together with an amine ligand or a base and a reducing agent (sodium ascorbate) to prevent 
aerobic oxidation to CuII.129 Reported at the same time by two groups, Medal (Denmark)130 and 
Fokin and Sharpless (US),130 the CuAAC  exclusively transforms organic azides and terminal 
alkynes into the corresponding 1,4-disubstituted 1,2,3-triazoles ─ unlike the uncatalysed reaction 
which needs higher temperatures and yields mixtures of 1,4- and 1,5-triazole regioisomers.130  
The reaction has been found to offer a straight-forward way of connecting building blocks 
having various functional groups, has proved to be dependable and offers high levels of 
compatibility between reactants.128,130  In our group, two approaches have been used in CuAAC, 
CuII together with sodium ascorbate as reducing agent and CuI with Et3N. In the present 
investigation, CuI and Et3N were used (Scheme 15). 
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Scheme 15. Click reaction of propargylamino derivatives 111a-c with AZT. 
Table 7. Yields of hydroxy ester-AZT conjugates 107a-c. 
Compound R1 Isolated Yields (%)
107a1* Br 72 
107a2* Br 36 
107b Cl 92 
107c1 H 55 
                                            * Diastereomers      
 
The yields ranged from 36-92%. The click reaction was conducted with each of the two 
diastereomeric propargylamino ester derivatives 111a1 and 111a2 with yields for the major and 
minor diastereomers being 72% and 36%, respectively. For the propargylamino derivative 111c 
only the major isomer, 111c1 was used in the click reaction. The DEPT 135 NMR spectrum 
(Figure 29) shows the various methyl, methylene and methine signals for compound 107b with 
the expected five methylene signals for CH2CHN, CH2NCH2CH, CH2OH and ArOCH2 at 39.0, 
44.5, 48.8, 62.1 and 71.5 ppm, respectively. The HSQC spectrum (Figure 30) clearly shows 
three of the methylene signals highlighted in the DEPT 135 NMR spectrum. Of particular 
interest are the correlations between the CH2CHN methylene carbon (resonating at 39.0 ppm) 
with the corresponding methylene protons which resonate separately at 2.68 and 2.79 ppm, 
reflecting their inherent diastereotopicity. The correlations between the CH2OH methylene 
carbon (resonating at 62.1 ppm) and its corresponding methylene protons at 3.75 and 3.84 ppm 
reveal the same pattern. 
111a-c 97 107a-c 
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Figure 29. DEPT 135 NMR spectrum of compound 107b in CD3OD. 
  
 
Figure 30. HSQC spectrum of compound 107b in CD3OD. 
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2.1.5. Synthesis of β-hydroxypropionate ester-AZT conjugates from unprotected 
salicylaldehydes 
 
Unlike their methyl ester analogues, Baylis-Hillman adducts derived from reactions between 
tert-butyl acrylate and salicylaldehydes are stable and isolable. Consequently, they can be used 
as substrates in subsequent reactions without the danger of uncontrolled cyclisation and without 
the need to benzylate the phenolic group in the salicylaldehyde precursors. In this study, five 
different salicylaldehydes were used. The general reaction pathway to the β-hydroxy ester-AZT 
conjugates is shown in Scheme 16. 
 
Scheme 16. Synthesis of of β-hydroxy ester-AZT conjugates from non-benzylated 
salicylaldehydes. 
 
 
Compound R1 R2 
115a Br H 
115b Cl H 
115c H H 
115d H OMe 
115e H OEt 
112a-e  113a-e
97 114a-e 
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2.1.6. Baylis-Hillman reactions with tert-butyl acrylate 
The salicylaldehydes 112a-e were reacted with tert-butyl acrylate in DABCO-catalysed Baylis-
Hillman reactions using CHCl3 as solvent. The reactions were allowed to run for 7-21 days with 
stirring at room temperature. The bromo- and chlorosalicylaldehyde products 113a and 113b had 
formed significantly after 4 days but the reactions were allowed to run for 7 days to enhance the 
yield. Work-up afforded the Baylis-Hillman adducts in yields ranging from 21 to 69% after 
chromatography (Table 8). The methoxy- and ethoxy-substituted salicylaldehyde adduct yields 
were particularly low. Further study aimed at improving the yields is an avenue that may be 
pursued. The 1H NMR spectrum (Figure 31) of tert-butyl 3-(5-chloro-2-hydroxyphenyl)-3-
hydroxy-2-methylenepropanoate, 113b, which is representative for the series, shows the tert-
butyl singlet at 1.31 ppm. The vinylic proton signals appear as singlets at 5.64 and 6.05 ppm with 
the upfield signal overlapping with the 4-methine proton signal. The three aromatic proton 
signals appear between 6.7 and 7.1 ppm. The DEPT 135 NMR spectrum shows the tert-butyl 
methyl  carbon signal at 27.6 ppm, the 4-methine carbon signal at 64.6 ppm and the vinylic CH2 
carbon signal at 123.1 ppm (Figure 32). 
Table 8. Yields of the tert-butyl adducts 113a-e. 
 
Compound R1 R2 Isolated yields (%)
113a Br H 69 
113b Cl H 54 
113c H H 36 
113d H OMe 26 
113e H OEt 21 
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Figure 31. 400 MHz 1H NMR spectrum of compound 113b in DMSO-d6. 
  
Figure 32. DEPT 135 NMR spectrum of compound 113b in DMSO-d6. 
C(CH3)3 
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2.1.7. Synthesis of propargylamino derivatives 114a-e  
A similar method to that described for the O-benzylated adducts in Section 2.1.3 was used to 
prepare compounds 114a-e in yields ranging from 46 to 84% (Table 9). The 1H NMR spectrum 
of compound 114b confirms the formation of the propargylamino products (Figure 33). The 
absence of the vinylic proton signals of the precursor and the presence of the signals at 2.57, 3.35 
and 5.21 ppm corresponding to C≡CH, CH2C≡CH and CHOH, respectively confirm the 
formation of the propargylamino product. The DEPT 135 spectrum (Figure 34) shows the two 
expected methylene carbon signals, an intense tert-butyl methyl signal and three aromatic 
methine carbon signals consistent with the expected product.  The DEPT 135 spectrum also 
shows a signal at 82 ppm for the quaternary alkyne carbon signal as discussed for the O-
benzylated propargyl compounds (Section 2.1.3.) The propargyl products, as described earlier, 
carry the propargyl moiety which enables the subsequent click reaction with AZT. 
 
Table 9. Yields of propargylamino derivatives 114a-e. 
 
 
Compound R1 R2 Isolated yields (%)
114a Br H 77 
114b Cl H 84 
114c H H 57 
114d H OMe 67 
114e H OEt 46 
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Figure 33. 600 MHz 1H NMR spectrum of compound 114b in CD3OD. 
  
Figure 34. DEPT 135 NMR spectrum of compound 114b CD3OD. 
NCH2 CH2N
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2.1.8. Click reactions of the propargylamino derivatives 114a-e 
The propargyl derivatives 114a-e were reacted with AZT in CH3CN in the presence of a Cu1 
catalyst and Et3N (Scheme 27). The reaction mixtures were allowed to stir at room temperature 
for 48 hours after which purification was achieved using column chromatography [on silica gel; 
elution with hexane  ̶  EtOAc (2:1)] except for the methoxy substituted derivative 115d, for 
which the purification described for the benzylated derivatives was used and which afforded 
better yields. Time constraints prevented the use of the better yielding purification method for 
the rest of the non-benzylated derivatives. The yields ranged from 10 to 66% with 115d having 
an outstandingly high yield when compared to the rest which are all below 20% (Table 10). The 
13C NMR spectrum of 115b reveals the tert-butyl methyl carbon signal at 12.5, the tert-butyl 
quartenary carbon signal at 82.2 and the ester carbonyl signal at 173.5 ppm (Figure 35). The 
spectrum also shows the expected number of carbon signals. The DEPT 135 spectrum (Figure 
36) shows the 4 expected methylene carbon signals, the upfield AZT methyl signal, the intense 
tert-butyl methyl carbon signal and 5 aromatic methine carbon signals consistent with the 
expected product.   
 
Scheme 17. Click reaction of propargylamino derivatives 114a-e with AZT. 
Table 10. Yields of propargylhydroxy ester-AZT conjugate 115a-e. 
Compound R1 R2 Isolated yields (%)
115a Br H 13 
115b Cl H 14 
115c H H 16 
115d H OMe 66 
115e H OEt 10 
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Results and discussion	
 
52 
 
 
Figure 35. 100 MHz 13C NMR spectrum of isomers of compound 115b in CD3OD. 
  
Figure 36. DEPT 135 NMR spectrum of compound 115b in CD3OD. 
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2.2. EXPLORATORY STUDIES ON ACCESSING 4-HYDROXYCOUMARINS   
 
In Section 1.3.3. the importance of 4-hydroxycoumarins as bioactive compounds with a wide 
range of activities was discussed. In this study, several approaches were explored to access these 
important compounds. Two of the approaches are shown in Schemes 18 and 19.  
 
Scheme 18. Proposed route to 4-hydroxycoumarins via cinnamate ester derivatives. 
 
2.2.1. Cinnamate ester route to 4-hydroxycoumarins 
The 2-(bromomethyl) cinnamate ester derivatives were formed in yields of up to 86% (Table 11) 
by reacting the Baylis-Hillman adducts 106a-c with LiBr in conc. H2SO4. The 1H NMR spectrum 
of compound 116a shows the methyl, 2-bromomethylene and benzylic proton signals at 3.87, 
4.33 and 5.12 ppm, respectively (Figure 37). The vinylic proton signals for the precursor are 
absent in the product and the new vinylic proton signal appears downfield at 7.96 ppm. The 
DEPT 135 spectrum (Figure 38) shows the expected two methylene carbon signals at 26.6 and 
70.6 ppm and the expected seven aromatic and vinylic methine carbon signals. 
Compound R 
a Br 
b Cl 
c H 
106a-c110a-c 116a-c 
117a-c118a-c119a-c 120a-c 
Results and discussion	
 
54 
 
Table 11. Yields of cinnamate ester derivatives 116a-c. 
 
 
Compound R Isolated Yields (%)
116a Br 86 
116b Cl 84 
116c H 55 
 
 
Figure 37. 400 MHz 1H NMR spectrum of compound 116a in CDCl3. 
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Figure 38. DEPT 135 NMR spectrum of compound 116a in CDCl3. 
Following preliminary studies in our group, the brominated cinnamate ester derivatives 116a-c 
were then reacted with potassium phthalimide affording the phthalimido-systems 117a-c.  The 
phthalimido-ester derivatives were obtained in yields of up to 86% after purification by column 
chromatography (Table 12). The 1H NMR spectrum of compound 117a reveals the methyl and 
benzylic proton signals as singlets at 3.69 and 5.04 ppm, respectively (Figure 39). The vinylic 
proton signals appear as singlets at 5.68 and 6.56 ppm. The DEPT 135 spectrum shows the 
methyl and the benzylic and vinylic methylene carbons resonating at 52.2, 70.3 and 129.1 ppm, 
respectively (Figure 40). The eight aromatic methine carbon signals appear as expected. 
Cyclisation of these adducts 117 using hydrogen and a Pd/C catalyst was expected to afford the 
phthalimido-coumarin systems 118a-c with the phthalimide moiety at position 4. It was hoped 
that aromatisation, followed by hydrolysis would provide access to 4-aminocoumarin systems 
and subsequently 4-hydroxycoumarin systems. Attempts to synthesise the 4-
 
OCH2 CH2Br 
OCH3
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phthalimidocoumarin with both the 5-bromo- and 5-chloro precursors proved unsuccessful. No 
attempt was done for the unsubstituted precursor. 
Table 12. Yields of phthalimido-ester derivatives 117a-c. 
 
Compound R1 Isolated Yields (%)
117a Br 84 
117b Cl 79 
117c H 86 
 
 
Figure 39. 400 MHz 1H NMR spectrum of compound 117a in CDCl3. 
OCH3 
OCH2PhC=CH2 
116a-c 117a-c
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Figure 40. DEPT 135 NMR spectrum of compound 117a in CDCl3. 
 
2.2.2. 3-(Chloromethyl)coumarin route to 4-hydroxycoumarin 
In another approach, acid-catalysed cyclisation of the Baylis-Hillman adduct afforded the 3-
(chloromethyl)coumarin which was then reacted with potassium phthalimide in the hope of 
attaching the phthalimide moiety at position 4. Aromatisation, followed by hydrolysis of the 4-
phthalimidocoumarin, was then expected to provide access to aminocoumarin systems and 
subsequently 4-hydroxycoumarin systems. The acid-catalyzed cyclisation of O-benzylated 
Baylis-Hillman adducts is considered to involve initial conjugate addition of HCl thus inhibiting 
attack at the resulting tetrahedral chloromethylene centre (necessary for chromene formation) 
and favouring the formation of coumarins.118 Methyl 3-(2-benzyloxy-5-chlorophenyl)-3-
hydroxy-2-methylpropanoate 106b was consequently cyclised to the corresponding coumarin 
derivative 121  using HCl, AcOH and Ac2O (Scheme 19). 
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Scheme 19. Proposed route to 4-hydroxycoumarin via acid catalyzed coumarin synthesis. 
 
The resulting coumarin 121 was then reacted with potassium phthalimide in the hope of forming 
the 4-phthalimido-coumarin via allylic (SN`) substitution; aromatisation and hydrolysis was then 
expected to provide access to 4-aminocoumarin systems and, subsequently, the desired 4-
hydroxycoumarin products. The yield of the 3-(chloromethyl)coumarin 121 was 80%. The 1H 
NMR spectrum of compound 121 reveals the methylene protons resonating as a singlet at 4.52 
ppm and the 4-methine proton as a singlet at 7.80 ppm (Figure 41). The 13C NMR (Figure 42) 
spectrum shows the expected 10 carbon signals and the DEPT 135 spectrum shows the expected 
aromatic methine carbon signals (Figure 43) and the methylene carbon signal at 40.8 ppm. 
105b  106b
123  122
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Figure 41.  600 MHz 1H NMR spectrum of compound 121 in CDCl3. 
 
 
Figure 42. 100 MHz 13C NMR spectrum of compound 121 in CDCl3. 
 
CH2Cl 
 
4-CH 
CH2Cl 
Results and discussion	
 
60 
 
 
Figure 43. DEPT 135 NMR spectrum of compound 121 in CDCl3. 
 
Unfortunately, the desired SN` displacement of chloride by potassium phthalimide was not 
successful, and direct SN displacement occurred instead (Scheme 20), as confirmed by NMR and 
high resolution mass spectrometry data. Thus, the 1H NMR spectrum of the product 124 in 
CD2Cl2 (Figure 44) shows the methylene protons resonating as a singlet at 4.78 ppm and the 
expected aromatic methine proton signals. The presence of the methylene 1H and 13C signals 
confirm the formation of compound 124; the desired product 125 has no methylene group. Time 
constraints precluded further research on access to the desired 4-hydroxycoumarins using Baylis-
Hillman methodology  ̶  a challenge which will enjoy future attention. The 13C NMR spectrum in 
CD2Cl2 reveals 14 signals accounting for all 14 of the expected carbons (Figure 45). In the 
DEPT 135 spectrum the six aromatic methine carbon signals are quite apparent (Figure 46). 
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Scheme 20. Reaction of compound 121 with potassium phthalimide. 
 
 
Figure 44. 600 MHz 1H NMR spectrum of compound 124 in CD2Cl2. 
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Figure 45. 100 MHz 13C NMR spectrum of compound 124 in CD2Cl2. 
 
  
Figure 46. DEPT 135 NMR spectrum of compound 124 in CD2Cl2. 
 
CH2N 
 
CH2N
Results and discussion	
 
63 
 
2.3. EXPLORATORY STUDIES ON THE CONSTRUCTION OF CHIRAL BAYLIS-
HILLMAN CATALYSTS 
The general aim in this area has been to design and construct engineered reaction scaffolds 
capable of catalysing specific reactions and acting as “synthetic enzymes”. In this study, 
attention was given to such scaffolds capable of facilitating chiral Baylis-Hillman reactions. The 
scaffolds would have a cavity containing a hydroxyl group for hydrogen-bonding the activated 
alkene substrate and a nucleophilic tertiary amino group for conjugate addition to the activated 
alkene as illustrated in Scheme 31.  
 
Scheme 31. Possible H-bonding interaction between the catalytic scaffold and the activated 
alkene in the ‘reaction pocket’ (I); subsequent reaction with a tethered nucleophile (II); and 
Baylis-Hillman type reaction with an aldehyde (III). 
The intention was to construct borneol-10-sulfonamides such as compounds 126a-c (Figure 47), 
starting from D-(+)-camphor sulfonyl chloride, to serve as chiral Baylis-Hillman catalytic 
systems. 
 
Figure 47. Proposed chiral scaffolds for catalysing chiral Baylis-Hillman reactions. 
127a-c 
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Access to these compounds involved reaction of campor-10-sulfonyl chloride 128 with the 
aromatic amines 126a-c as illustrated in Scheme 32. 
O +
Et3NRNH2
CH2Cl2
OH
SO2NHR
NaBH4
SO2Cl
O
SO2NHR  
 
Scheme 32. Proposed synthesis of customized sulfonamide catalysts 127a-c. 
The coupling of each of the three amines 126a-c with camphor-10-sulfonyl chloride was 
expected to afford the camphor-10-sulfonamides 129a-c (Scheme 32), reduction of which would 
afford the catalytic scaffolds 127a-c. These systems would then be used in Baylis Hillman 
reactions with pyridine-4-carbaldehyde and methyl acrylate as Baylis-Hillman substrates and the 
reactions were to be monitored by 1H NMR spectroscopy. 
 
2.3.1. Synthesis of the sulfonamides 129a-c 
Reaction of camphor-10-sulfonyl chloride 128 with N-(3-aminopropyl)imidazole 126a using 
method A afforded the sulfonamide 129a in a yield of 74%(Table 13). The 1H NMR spectrum 
(Figure 48) of this compound reveals the methyl proton signals at 0.86 and 0.99 ppm, 
respectively. The three expected aromatic methine proton signals are present with the 16-H 
signal furthest downfield at 7.57 ppm. The 13C NMR spectrum (Figure 49) shows the expected 
sixteen carbon signals with the C-1 and C-2 signals at 59.0 and 217.0 ppm, respectively. The 
DEPT 135 spectrum (Figure 50) reveals the 4-methine carbon signal at 42.6 ppm and the 7 
expected methylene carbon signals at 26.3, 26.9, 31.5, 40.2, 42.9, 43.8 and 49.1 ppm. 
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Figure 48. 1H NMR spectrum of compound 129a in CDCl3. 
   
Figure 49. 13C NMR spectrum of compound 129a in CDCl3. 
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Figure 50. DEPT 135 NMR spectrum of compound 129a in CDCl3. 
 
Table 13. Camphor-10-sulfonamides 164a-c. 
 
 
 
Compound RNH2 Method Yield (%) 
129a 3-(imidazol-1-yl)propylamine A 74 
129b 2-picolylamine A 89 
129c 2-aminoimidazole.1/2 H2SO4 B 64 
 
 
  C-4 
Method A: Et3N, CH2Cl2 
Method B: KOH, DMAP, CH3CN 
128 129a-c 
Results and discussion	
 
67 
 
The camphor-10-sulfonamide 129b was obtained in a yield of 89% (Table 13) using method A 
and was fully characterized. The DEPT 135 spectrum (Figure 52) reveals the 4-methine carbon 
signal at 42.6 ppm and the five expected methylene carbon signals at 26.2, 26.9, 42.7, 48.3 and 
50.0 ppm, respectively. 2-Aminoimidazole 126c was supplied as the hemi-sulfate salt and, 
consequently, required neutralization to release the nucleophilic amino group. This reaction was 
therefore conducted in CH3CN using KOH as a base and DMAP as a nucleophilic acylation 
catalyst (method B). The desired camphor-10-sulfonamide 129c was obtained in a yield of 64% 
(Table 13) and was also fully characterized. The DEPT 135 spectrum (Figure 53) reveals the 4-
methine carbon signal at 44.0 ppm and the four expected methylene carbon signals at 25.7, 27.4, 
43.6 and 48.3 ppm respectively. 
  
 
Figure 51. DEPT 135 NMR spectrum of compound 129b in CDCl3. 
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Figure 52. DEPT 135 NMR spectrum of compound 129c in CDCl3. 
 
2.3.2. Synthesis of the bornyl-10-sulfonamides 
The camphor-10-sulfonamides 129a and 129b were reduced under mild conditions using NaBH4 
to give the corresponding sulfonamide alcohols in excellent yields of 98 and 92%, respectively 
(Table 14). Both compounds were fully characterised. The 1H NMR spectrum of the bornyl-10-
sulfonamide 127a shows the methyl proton singlets at 0.80 and 1.04 ppm, respectively (Figure 
54) and the three aromatic methine signals are clearly evident. The 13C NMR spectrum shows the 
expected 16 carbon signals with the C-1 and C-2 signals at 50.3 and 76.3 ppm, respectively 
(Figure 55); the C-2 signal, which appears at 217.1 in the 13C NMR spectrum of the camphor 
precursor 129a, is shifted upfield in spectrum of the alcohol 127a. The formation of the 2-exo-
alcohols in preference to the 2-endo diastereomers is attributed to the steric bulk of the 8-methyl 
group which inhibits exo attack by the hydride ion.131 
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Table 14. Bornyl-10-sulfonamides. 
 
 
Compound RNH2 Yield (%) 
162a 3-(imidazol-1-yl)propylamine 98 
162b 2-picolylamine 92 
 
Preliminary evaluation of the efficacy of the bornyl-10-sulfonamide 127a as a Baylis-Hillman 
catalyst in the reaction of pyridine-4-carbaldehyde with methyl acrylate failed to afford the 
desired adduct. Unfortunately, time constrains precluded further investigation at this stage. 
 
 
Figure 53. 1H NMR spectrum of compound 127a in CDCl3. 
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Figure 54. 13C NMR spectrum of compound 127a in CDCl3.  
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2.4. CONCLUSIONS 
 
This study has afforded opportunities for the application of Baylis-Hillman methodology in the 
synthesis of β-hydroxypropionate ester-AZT conjugates as potential dual-action HIV-1 IN/RT 
inhibitors, in which the AZT moiety serves as the RT inhibitor and the β-hydroxypropionate 
ester moiety serves as the IN inhibitor. The β-hydroxypropionate ester moiety is analogous to the 
DKAs which are known to inhibit HIV-1 IN. Nine β-hydroxypropionate ester-AZT conjugates 
were successfully synthesised from Baylis-Hillman propargylamino derivatives via ‘click’ 
chemistry cycloaddition with AZT.  Of the nine conjugates prepared, four were derived from O-
benzylated and five from non-benzylated salicylaldehyide Baylis-Hillman adducts.  The 
protected β-hydroxypropionate ester-AZT conjugate yields ranged from 36 to 92% whereas 
those of the protected β-hydroxypropionate ester-AZT conjugates ranged from 10 to 60%.  
Exploratory studies were also carried out to access 4-hydroxycoumarins from Baylis-Hillman 
derived adducts and to construct customised camphor-based chiral Baylis-Hillman reaction sites. 
Two qpproaches to the desired 4-hydroxycoumarins were explored, unfortunately without 
success in both cases. Two borneol-10-sulfonamides were constructed as chiral, Baylis-Hillman 
catalystic sites in several steps. Preliminary evaluation of these compounds as Baylis-Hillman 
catalysts however, revealed them to be inactive under the conditions employed. 
Future work in these areas is expected to include the following objectives. 
i) Optimisation of the yields of the β-hydroxypropionate ester-AZT conjugates from the 
non-protected salicylaldehydes. 
ii) Evaluation of both classes of β-hydroxypropionate ester-AZT conjugates as potential 
dual-action HIV-1 IN/RT inhibitors using bioassay data and computer-simulated 
docking. 
iii) Further investigation into accessing 4-hydroxycoumarins using Baylis-Hillman 
methodology. 
iv) Use of computer-aided design to construct camphor-based customised chiral Baylis-
Hillman catalysts. 
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3. EXPERIMENTAL 
3.1. GENERAL 
Reagents were used as supplied by Sigma-Aldrich without further purification.  The drying of 
solvents was carried out following procedures described by Perrin and Armarego.132 Thin layer 
chromatography was carried out on pre-coated Merck silica gel F254 plates, and viewed under 
UV light (254 / 365 nm) or following exposure to iodine. Flash chromatography was carried out 
using Merck silica gel 60 (particle size 0.040-0.063 mm) and preparative layer chromatography 
was conducted using Macherey-Nagel silica gel P / UV254. 
NMR spectra were recorded on Bruker AMX 400 MHz and Biospin 600 MHz spectrometers and 
were referenced using residual protonated solvent signals (δH: 7.26 ppm for CDCl3, 5.32 ppm for 
CD2Cl2, 2.50 ppm for DMSO-d6  and 3.31 ppm for CD3OD; δC: 77.0 ppm for CDCl3, 53.84 ppm 
for CD2Cl2, 39.5 ppm for DMSO-d6, and 49.0 ppm for CD3OD). High resolution mass spectra 
were recorded on a Waters API Q-TOF Ultima spectrometer (University of Stellenbosch, South 
Africa). IR spectra were recorded on a Perkin-Elmer FT-IR Spectrum 100 spectrometer (neat). 
Melting points were measured using a Reichert 281313 hot-stage apparatus, and are uncorrected. 
 
3.2. PREPARATION OF O-BENZYLATED 3-HYDROXYPROPANAOATE ESTER-AZT 
CONJUGATES 
2-(Benzyloxy)-5-bromobenzaldehyde 105a 
 
To 5-bromosalicylaldehyde (6.4 g, 32 mmol) in 10% NaOH (aq) (15 mL) was added benzyl 
bromide  (3.8 ml, 32 mmol) and the mixture heated under reflux with stirring for 30 minutes. The 
mixture was cooled, water added (50 mL) and the solid which formed was filtered and washed 
thoroughly with water and dried. The solid was then crystallised from hexane and dried under 
vacuum to yield 2-(benzyloxy)-5-bromobenzaldehyde 105a as a cream solid (8.1 g, 87 %), m.p. 
73-74 oC (lit.133 73-74 oC); ʋmax/cm-1 1677 (C=O); δH (400 MHz; CDCl3) 5.18 (2H, s, OCH2Ph), 
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6.95 (1H, d, J = 9.0 Hz, ArH), 7.37-7.43 (5H, overlapping m, ArH), 7.60 (1H, dd, J = 8.9 and 2.7 
Hz, ArH), 7.94 (1H, d, J = 2.6 Hz, ArH) and 10.46 (1H, s, CHO); δC (100 MHz; CDCl3) 70.8 
(OCH2Ph), 113.8, 115.1, 126.4, 127.3, 128.5, 128.8, 131.0, 135.5 and 138.2 (Ar-C), 159.8 
[Ar(OBn)] and 188.3 (C=O). 
2-(Benzyloxy)-5-Chlorobenzaldehyde 105b 
 
The procedure described for the synthesis of 2-(benzyloxy)-5-bromobenzaldehyde was employed 
using 5-chlorosalicylaldehyde (5 g, 32 mmol), 10% NaOH (aq) (15 mL), and benzyl bromide 
(3.8mL, 32 mmol). Work-up afforded 2-(benzyloxy)-5-chlorobenzaldehyde 105b as a cream 
solid (6.4 g, 81 %), m.p.70-72 oC (lit.134 70-72 oC); ʋmax/cm-1 1678 (C=O); δH (400 MHz; CDCl3) 
5.18 (2H, s, OCH2Ph), 6.95 (1H, d, J = 8.9 Hz, ArH), 7.36-7.43 (5H, overlapping m, ArH), 7.60 
(1H, dd, J = 8.9 and 2.7 Hz, ArH), 7.94 (1H, d, J = 2.6 Hz, ArH) and 10.46 (1H, s, CHO); δC 
(100 MHz; CDCl3) 70.8 (OCH2Ph), 113.8, 115.1, 126.4, 127.3, 128.5, 128.8, 131.0, 135.5 and 
138.2 (Ar-C), 159.8 [Ar(OBn)] and 188.3 (C=O). 
2-Benzyloxybenzaldehyde 105c122 
 
The procedure described for the synthesis of 2-(benzyloxy)-5-bromobenzaldehyde was employed 
using salicylaldehyde (3.4 mL, 32 mmol), 10% NaOH (aq) (15 mL), and benzyl bromide (3.8 
mL, 32 mmol). Work-up afforded 2-benyloxybenzaldehyde 105c as a brown gel (4.4 g, 65 %); 
ʋmax/cm-1 1678 (C=O); δH (400 MHz; CDCl3) 5.20 (2H, s, OCH2Ph),7.06 (1H, d, J = 8.0 Hz, 
ArH), 7.36-7.46 (5H, overlapping m, ArH), 7.54 (1H, td, J = 8.0 and 1.2 Hz, ArH), 7.87 (1H, dd, 
J = 7.7 and 1.8 Hz, ArH) and 10.57 (1H, s, CHO); δC (100 MHz; CDCl3) 70.4 (OCH2Ph), 113.0, 
121.0, 125.1, 127.2, 128.2, 128.4, 128.7, 135.9 and 136.0 (Ar-C), 151.0 [Ar(OBn)] and 189.7 
(C=O). 
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Methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-2-methylenepropanoate 106a 
 
A mixture of 2-benzyloxy-5-bromobenzaldehyde 105a (4.7 g, 16 mmol), methyl acrylate (2.9 
mL, 32 mmol) and DABCO (0.45 g, 4 mmol) in CHCl3 (10 mL) was stirred at room temperature 
for 21 days. The mixture was concentrated under vacuum and purified using column 
chromatography [elution with hexane-EtOAc (4:1)] to afford methyl 3-(2-benzyloxy-5-
bromophenyl)-3-hydroxy-2-methylenepropanoate 106a as a white solid (3.2 g, 54%), m.p. 76-77 
oC(lit.134 114-116 oC); ʋmax/cm-1 3340 (OH) and 1719 (C=O); δH (400 MHz; CDCl3) 3.74 (3H, s, 
OCH3), 5.05 (2H, s, OCH2Ph), 5.66 and 6.30 (2H, 2 x s, C=CH2), 5.89 (1H, s, CHOH), 6.80 (1H, 
d, J = 8.7 Hz, ArH), 7.32-7.40 (6H, overlapping m, ArH) and 7.54 (1H, d, J = 2.5 Hz, ArH); δC 
(100 MHz; CDCl3) 52.0 (OCH3), 67.7 (CHOH), 70.4 (OCH2Ph), 126.5 (C=CH2), 113.5, 113.6, 
127.3, 128.2, 128.6, 130.6, 131.5, 131.8, 136.2, 140.6 and 154.6 (C=CH2 and Ar-C) and 166.9 
(C=O). 
Methyl 3-(2-benzyloxy-5-chlorophenyl)-3-hydroxy-2-methylenepropanoate 106b 
O
OBn
Cl
OH O
 
The procedure described for the synthesis of methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-
2-methylpropanoate 106a was employed using 2-benzyloxy-5-chlorobenzaldehyde 105b (4 g, 16 
mmol), methylacrylate (2.9 mL, 32 mmol) and DABCO (0.45 g, 4 mmol) in CHCl3 (10 mL). 
Work up afforded methyl 3-(2-benzyloxy-5-chlorophenyl)-3-hydroxy-2-methylenepropanoate 
106b as a white solid (3.2 g, 61%), m.p. 78-80 oC (lit.118 reported as an oil); ʋmax/cm-1 3397 (OH) 
and 1712 (C=O); δH (400 MHz; CDCl3) 3.74 (3H, s, OCH3), 5.05 (2H, s, OCH2Ph), 5.66 and 
6.30 (2H, 2 x s, C=CH2), 5.89 (1H, s, CHOH), 6.84 (1H, d, J = 8.7 Hz, ArH), 7.19 (1H, d, J = 
8.77 Hz, ArH) and 7.31-7.42 (6H, overlapping m, ArH); δC (100 MHz; CDCl3) 52.0 (OCH3), 
67.8 (CHOH), 70.5 (OCH2Ph), 126.5 (C=CH2), 113.1, 126.1, 127.3, 127.7, 128.0, 128.2, 128.6, 
131.4, 136.2, 140.6 and 154.1 (C=CH2 and Ar-C) and 166.9 (C=O). 
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Methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylpropanoate 106c122  
O
OBn
OH O
 
The procedure described for the synthesis of methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-
2-methylpropanoate 106a was employed using 2-benzyloxybenzaldehyde 105c (3.4 g, 16 mmol), 
methyl acrylate (2.9 mL, 32 mmol) and DABCO (0.45 g, 4 mmol) in CHCl3 (10 mL). Work up 
afforded methyl 3-(2-benzyloxyphenyl)-3-hydroxy-2-methylpropanoate 106c as a yellow oil (3.1 
g, 64%); ʋmax/cm-1 3485 (OH) and 1716 (C=O); δH (400 MHz; CDCl3) 3.46 (1H, br s, OH), 3.72 
(3H, s, OCH3), 5.09 (2H, s, OCH2Ph), 5.70 and 6.30 (2H, 2 x s, C=CH2), 5.94 (1H, s, CHOH), 
6.92-7.02 (2H overlapping m, ArH) and 7.32-7.42 (6H overlapping m, ArH); δC (100 MHz; 
CDCl3) 51.9 (OCH3), 68.5 (CHOH), 70.1 (OCH2Ph), 125.9 (C=CH2), 111.8, 121.0, 127.3, 127.8, 
128.0, 128.6, 128.8, 129.5, 136.6, 141.2 and 155.7 (C=CH2 and Ar-C) and 167.0 (C=O). 
Methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 
diastereomers 111a1 and 111a2 
 
To a solution of methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-2-methylenepropanoate 
106a (0.4 g, 1.1 mmol) in dry THF (1.5 mL) was added propargylamine (0.192 mL, 3 mmol) and 
the mixture stirred at r.t. for 3 days. The mixture was then concentrated under vacuum and 
chromatographed [PLC on silica gel; elution with hexane-EtOAc (2:1) to afford both 
diastereomers of methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-2-[(2propynylamino)methyl] 
propanoate. Diastereomer 111a1 as a cream solid (0.39 g, 84%), m.p. 78-82 oC; [HMRS: m/z 
calculated for C21H23BrNO4 (MH+) 432.0810. Found 432.0807]; ʋmax/cm-1 3283 (OH) and 1719 
(C=O); δH (400 MHz; CDCl3) 2.19 (1H, t, J = 2.5 Hz, C≡CH), 2.88 (1H, dd, J = 5.4 and 11.8 Hz, 
CHCO), 3.07-3.17 (2H, m, CHCH2), 3.35 (2H, qd, J = 2.7 and 17.1 CH2-C≡CH), 3.54 (3H, s, 
OCH3), 5.03-5.12 (2H, m, OCH2), 5.34 (1H, d, J = 4.2 Hz, CHOH), 6.79 (1H, d, J = 8.7 Hz, 
ArH), 7.29-7.46 (6H, overlapping m, ArH) and 7.55 (1H, d, J = 2.5 Hz, ArH); δC (100 MHz; 
CDCl3) 38.1 and 48.6 (NCH2), 49.6 (CHCO), 51.5 (CH3), 69.7 (CHOH), 70.3 (OCH2) 71.8 and 
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81.2 (C≡CH), 113.1, 113.5, 127.2, 128.2, 128.7, 130.0, 130.9, 132.6, and 136.2 (Ar-C), 153.9 
[ArC(OBn)] and 173.6 (C=O). 
Diastereomer 111a2, as cream solid (0.31 g, 66%) m.p. 68-70 oC; [HMRS: m/z calculated for 
C21H23BrNO4 (MH+) 432.0810. Found 432.0816]; ʋmax/cm-1 3336 (OH) and 1719 (C=O); δH (400 
MHz; CDCl3) 2.29 (1H, q, J = 2.9 and 3.4 Hz, C≡CH), 2.58 (1H, dd, J = 3.7 and 12.4 Hz, 
CHCHa), 3.09 (1H, q, J = 3.4 Hz, CHCO), 3.20 (1H, dd, J = 3.2 and 12.5 Hz, CHCHb), 3.37 
(2H, qd, J = 2.6 and 17.0 CH2-C≡CH), 3.76 (3H, s, OCH3), 5.08 (2H, t, J = 5.7 Hz, OCH2), 5.71 
(1H, d, J = 3.1 Hz, CHOH), 6.80 (1H, d, J = 8.6 Hz, ArH), 7.27-7.48 (6H, overlapping m, ArH) 
and 7.72 (1H, d, J = 2.7 Hz, ArH); δC (100 MHz; CDCl3) 38.3 and 45.6 (NCH2), 46.9 (CHCO), 
52.1 (CH3), 70.0 (OCH2) 71.4 (CHOH), 72.4 and 80.6 (C≡CH), 113.1, 113.6, 126.7, 127.9, 
128.5, 130.3, 130.9, 133.8, and 136.4 (Ar-C), 153.5 [ArC(OBn)] and 173.8 (C=O). 
Methyl 3-(2-benzyloxy-5-chlorophenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 
111bas a mixture of diastereomers 
 
The procedure described for the synthesis of methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-
2-[(2-propynylamino)methyl]propanoate 111a was followed using 3-(2-benzyloxy-5-
chlorophenyl)-3-hydroxy-2-methylenepropanoate 106b (0.37, 1.1 mmol) in dry THF (1.5 mL) 
and propargylamine (0.192 mL, 3 mmol). Work-up afforded methyl 3-(2-benzyloxy-5-
chlorophenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 111b as a cream solid (0.41 
g, 97%), m.p. 88-92 oC; [HMRS: m/z calculated for C21H23ClNO4 (MH+) 388.1316. Found 
388.1320]; ʋmax/cm-1 3460 (OH) and 1717 (C=O); δH (400 MHz;  MeOD-d4) 2.48 (1H, t, J = 2.6 
Hz, C≡CH), 2.60-2.67  (1H, m, CHCO), 2.90-3.00 (2H, m, CHCH2), 3.19 (2H, d, J = 2.6 Hz, 
CH2-C≡CH),3.56 (3H, d, J = 4.3 Hz,OCH3), 5.09 (2H, d, J = 2.7 Hz, OCH2), 5.26 (1H, d, J = 6.1 
Hz, CHOH), 6.99 (1H, d, J = 8.8 Hz, ArH), 7.19 (1H, dd, J = 2.8 and 8.7 Hz, ArH) and 7.29-7.50 
(6H, overlapping m, ArH); δC (100 MHz; MeOD-d4) 38.2 and 48.4 (NCH2), 52.1 (CHCO), 53.6 
(CH3), 68.2 (CHOH), 71.6 (OCH2), 73.4 and 81.8 (C≡CH), 114.4, 127.0, 128.2, 128.7, 129.1, 
129.2, 129.7, 134.5 and 138.1 (Ar-C), 155.3 [Ar(OBn)] and 175.1 (C=O). 
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Methyl 3-(2-(benzyloxyphenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 
diastereomers 111c1 and 111c2 
 
The procedure described for the synthesis of methyl 3-(2-benyloxy-5-bromophenyl)-3-hydroxy-
2-[(2-propynylamino)methyl]propanoate 111a was followed using methyl 3-(2-
benzyloxyphenyl)-3-hydroxy-2-methylenepropanoate 106c (0.33, 1.1 mmol) in dry THF (1.5 
mL) and propargylamine (0.192 mL, 3 mmol). Work-up afforded both diastereomers of methyl 
3-(2-(benzyloxy)phenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate. Diastereomer 
111c1 as a yellow oil (0.30 g, 76%); [HMRS: m/z calculated for C21H24NO4 (MH+) 354.1705. 
Found 354.1695]; ʋmax/cm-1 (C=O); δH (400 MHz; CDCl3) 2.14-2,19 (1H, m, C≡CH), 2.90 (1H, 
dd, J = 6.6 and 12.0 Hz, CHCHa), 3.01 (1H, dd, J = 4.7 and 12.1 Hz, CHCHb), 3.14 (1H, t, J = 
5.7 Hz, CHCO), 3.29-3.41 (2H, m, CH2 -C≡CH), 3.55 (3H, s, OCH3), 5.06-5.14 (2H, m, OCH2), 
5.32 (1H, d, J = 5.3 Hz, CHOH), 6.90-7.02 (2H, m, ArH) and 7.30-7.45 (7H, overlapping m, 
ArH); δC (100 MHz; CDCl3) 38.0 and 48.4 (NCH2), 50.4 (CHCO), 51.5 (CH3), 70.0 (OCH2), 
70.2 (CHOH), 71.6 and 81.4 (C≡CH), 111.4, 120.9, 127.16, 127.22, 128.0, 128.5, 128.6, 130.0 
and 136.7 (Ar-C), 155.0 [ArC(OBn)] and 174.1 (C=O). 
Diastereomer 111c2 as a yellow oil; [HMRS: m/z calculated for C21H24NO4 (MH+) 354.1705. 
Found 354.1699]; ʋmax/cm-1 (C=O); δH (400 MHz;  CDCl3) 2.18 (1H, m, C≡CH), 2.53 (1H, dd, J 
= 3.9 and 12.3 Hz, CHCHa), 3.15 (1H, q, J = 3.5 Hz CHCO), 3.19-3.29 (2H, m,  CHCHb and 
CHa-C≡CH), 3.41, 3.37-3.47 (1H, m, CHb-C≡CH), 3.76 (3H, s, OCH3), 5.07-5.16 (2H, m, 
OCH2), 5.73 (1H, d, J = 3.5 Hz, CHOH), 6.94 (1H, d, J = 8.2 Hz, ArH), 7.04 (1H, t, J = 7.5 Hz, 
ArH),  7.23-7.49 (6H, overlapping m, ArH) and 7.54-7.58 (1H, m, ArH); δC (100 MHz; CDCl3) 
38.3 and 45.9 (NCH2), 47.5 (CHCO), 52.0 (CH3), 69.6 (OCH2), 71.7 (CHOH), 72.1 and 80.8 
(C≡CH), 111.4, 120.8, 126.7, 127.1, 127.7, 128.3, 128.4, 131.2 and 136.9 (Ar-C), 154.5 
[ArC(OBn)] and 174.1 (C=O). 
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O-Benzylated 3-hydroxypropanoate ester-AZT conjugate diastereomer 101a1  
 
Methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 
111a1 (0.086 g, 0.2 mmol) was dissolved in CH3CN (1 mL) and 3`-azidodeoxythymidine AZT 
(0.059 g, 0.22 mmol), Et3N (33 µL) and CuI (0.0038 g) were added to the solution. The mixture 
was stirred for 48 hours then diluted with DCM (10 mL), washed with saturated aq. NH4Cl 
solution (5 mL), followed by brine (5 mL), and dried over magnesium sulfate. The organic 
solution was concentrated under vacuum and the crude product purified by column 
chromatography [on silica gel; elution with EtOAc and then with EtOAc-methanol (1-4)] to 
afford O-benzylated 3-hydroxypropanoate ester-AZT conjugate 101a1 as a pale yellow solid (0.1 
g, 72%), m.p. 96-100 oC; [HMRS: m/z calculated for C31H36BrN6O8 (MH+) 699.1778. Found 
699.1805]; ʋmax/cm-1 1683 (C=O); δH (400 MHz; CD3OD) 1.87 (3H, s, CH3), 2.53 (1H, td, J = 
4.8, 9.0 and 10.4 Hz, CHaCHN), 2.60-2.70 (1H, m, CHCHaN), 2.79 (1H, dd, J = 6.5 and 13.9 Hz,  
CHCHbN), 2.87 (1H, t, J = 10.4 Hz, CHbCHN), 2.95-3.01 (1H, m, CHCO), 3.55 (3H, s, OCH3), 
3.7 (3H, dq, J = 4.8, 6.0 and 11.4 Hz, CH2OH and CHaCN), 3.82-3.87 (1H, m, CHbCN),  4.21-
4.28 (1H, m, OCHCHN), 5.06 (2H, s, OCH2Ph), 5.21-5.26 (1H, m, CHOH), 5.28-5.34 (1H, m, 
OCHCH2OH), 6.42 (1H, t, J = 6.4 Hz, OCHN),  6.91 (1H, d, J = 8.8 Hz, ArH), 7.30 (4H, dt, J = 
7.8 and 17.5 Hz, ArH), 7.40 (2H, d, J = 7.3 Hz, ArH), 7.49 (1H, d, J = 2.6 Hz, ArH), 7.78 (1H, s, 
ArH) and 7.88 (1H, s, ArH); δC (100 MHz; CD3OD) 12.5 (CH3Ar), 39.1 (CH2CHN), 44.6 and 
48.8 (CH2N), 52.1 (OCH3), 53.7 (CHCO), 60.9 (CHN), 62.1 (CH2OH), 68.2 (CHOH), 71.5 
(OCH2Ph), 86.4 (HOCH2CHO), 86.6 (NCHO), 111.7, 114.2, 115.0, 123.76, 123.83, 128.6, 
129.1, 129.7, 131.1, 132.3, 134.9, 138.1, 138.2, 147.08, 147.13, 152.3, 155.8, 166.4 and 175.1 
(Ar-C, C=C and C=O). 
O-Benzylated 3-hydroxypropanoate ester-AZT conjugate diastereomer 101a2 
Methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 
111a2 (0.086 g, 0.2 mmol) was dissolved in CH3CN (1 mL) and 3`-azidodeoxythymidine (0.059 
Experimental	
 
79 
 
g, 0.22 mmol), Et3N (33 µL) and CuI (0.0038 g) were added to the solution. The mixture was 
stirred for 48 hours then diluted with DCM (10 mL), washed with saturated aq. NH4Cl solution 
(5 mL), followed by brine (5 mL), and dried over magnesium sulfate. The organic solution was 
concentrated under vacuum and the crude product purified by column chromatography [on silica 
gel; elution with EtOAc and then with EtOAc-methanol (1-4)] to afford O-benzylated 3-
hydroxypropanoate ester-AZT conjugate diastereomer 101a2 as a pale yellow solid (0.05 g, 
36%), m.p. 97-100 oC; [HMRS: m/z calculated for C31H36BrN6O8 (MH+) 699.1778. Found 
699.1786]; ʋmax/cm-1 1683 (C=O); δH (400 MHz; CD3OD) 1.87 (3H, s, CH3), 2.46 (1H, dt, J = 
4.9, and 11.86 Hz, CHaCHN), 2.63 (1H, td, J = 5.4, 10.1 and 11.2 Hz, CHCHaN), 2.75 (1H, q, J 
= 6.0 and 6.7 Hz,  CHCHbN), 2.82 (1H, t, J = 11.4 Hz, CHbCHN), 3.00-3.07 (1H, m, CHCO), 
3.59 (3H, s, OCH3), 3.65-3.70 (3H, m, CH2OH and CHaCN), 3.77-3.89 (1H, m, CHbCN),  4.23 
(1H, t, J = 4.2 Hz, OCHCHN), 5.05 (2H, s, OCH2Ph), 5.27 (2H, t, J = 8.6 Hz, CHOH and 
OCHCH2OH), 6.40 (1H, dt, J = 6.3 and 11.5 Hz, OCHN),  6.94 (2H, dt, J = 7.9 and 13.8 Hz, 
ArH), 7.14-7.43 (6H, overlapping m, ArH), 7.71 (1H, d, J = 7.8 Hz, ArH) and 7.87 (1H, s, ArH); 
δC (100 MHz; CD3OD) 12.5 (CH3Ar), 39.0 (CH2CHN), 44.5 and 48.8 (CH2N), 52.2 (OCH3), 
54.2 (CHCO), 60.9 (CHN), 62.1 (CH2OH), 68.8 (CHOH), 71.2 (OCH2Ph), 86.4 (HOCH2CHO), 
86.7 (NCHO), 111.7, 113.0, 122.0, 123.7, 128.3, 128.5, 129.0, 129.4, 129.6, 129.80, 129.84, 
132.0, 138.2, 138.6, 147.1, 152.3, 156.8, 166.4 and 175.7 (Ar-C, C=C and C=O). 
O-Benzylated 3-hydroxypropanoate ester-AZT conjugate 101b 
 
The procedure described for the synthesis of 101a was followed using methyl 3-(2-benzyloxy-5-
chlorophenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 111b (0.16 g, 0.4 mmol), 
CH3CN (1 mL) and 3`-azidodeoxythymidine (0.12 g, 0.44 mmol), Et3N (67 µL) and CuI (0.008 
g). Work-up afforded O-benzylated 3-hydroxypropanoate ester-AZT conjugate 101b as a pale 
yellow solid (0.24 g, 92%), m.p. 86-90 oC; [HMRS: m/z calculated for C31H36ClN6O8 (MH+) 
655.2283. Found 655.2297]; ʋmax/cm-1 (C=O); δH (400 MHz;  CD3OD) 1.86 (3H, s, CH3), 2.53 
(1H, p, J = 5.0 Hz, CHaCHN), 2.58-2.70 (1H, m, CHCHaN), 2.72-2.82 (1H, m, CHCHbN), 2.87 
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(1H, t, J = 10.7 Hz, CHbCHN), 2.95-3.03 (1H, m, CHCO), 3.54 (3H, s, OCH3), 3.62-3.75 (3H, 
m,  CH2OH and CHaCN), 3.84 (1H, dd, J = 2.9 and 12.2 Hz, CHbCN),  4.24 (1H, dt, J = 3.2 and 
6.3 Hz, OCHCHN), 5.05 (2H, s, OCH2Ph), 5.23  (1H, dd, J = 2.0 and 6.8 Hz, CHOH), 5.30 (1H, 
dt, J = 5.4 and 9.9 Hz, OCHCH2OH), 6.42 (1H, t, J = 6.4 Hz, OCHN),  6.95 (1H, d, J = 8.7 Hz, 
ArH), 7.15 (1H, dd, J = 2.8 and 8.9 Hz, ArH), 7.24-7.42 (6H, overlapping m, ArH), 7.40 (2H, d, 
J = 7.3 Hz, ArH), 7.78 (1H, d, J = 2.3 Hz, ArH) and 7.87 (1H, s, ArH); δC (100 MHz; CD3OD) 
12.5 (CH3Ar), 39.0 (CH2CHN), 44.5 and 48.8 (CH2N), 52.1 (OCH3), 53.7 (CHCO), 60.9 (CHN), 
62.1 (CH2OH), 68.2 (CHOH), 71.5 (OCH2Ph), 86.4 (HOCH2CHO), 86.6 (NCHO), 111.6, 114.5, 
123.8, 123.9, 126.9, 128.1, 128.6, 129.1, 129.3, 129.7, 134.5, 138.1, 138.2, 147.0, 147.1, 152.2, 
155.3, 166.4 and 175.1 (Ar-C, C=C and C=O). 
  
O-Benzylated 3-hydroxypropanoate ester-AZT conjugate 101c 
 
The procedure described for the synthesis of 101a was followed using methyl 3-(2-
(benzyloxyphenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 111c (0.071 g, 0.2 
mmol), CH3CN (1 mL) and 3`-azidodeoxythymidine (0.059 g, 0.22 mmol), Et3N (33 µL) and 
CuI (0.0038 g). Work-up afforded O-benzylated 3-hydroxypropanoate ester-AZT conjugate 101c 
as a pale yellow solid (0.069 g, 55%), m.p. 64-66 oC; [HMRS: m/z calculated for C31H37N6O8 
(MH+) 621.2673. Found 621.2683]; ʋmax/cm-1 1683 (C=O); δH (400 MHz; CD3OD) 1.87 (3H, s, 
CH3), 2.48 (1H, dd, J = 6.0 and 11.25 Hz, CHaCHN), 2.63 (1H, td, J = 4.6 and 9.3 Hz, 
CHCHaN), 2.77 (1H, dd, J = 6.4 and 13.9 Hz, CHCHbN), 2.83 (1H, t, J = 11.0 Hz, CHbCHN), 
3.04 (1H, td, J = 4.6, 8.5 and 9.0 Hz, CHCO), 3.58 (3H, s, OCH3), 3.68 (3H, t, J = 7.25 Hz, 
CH2OH and CHaCN), 3.80-3.86 (1H, m, CHbCN),  4.19-4.26 (1H, m, OCHCHN), 5.07 (2H, s, 
OCH2Ph), 5.29 (2H, d, J = 7.6 Hz, CHOH and OCHCH2OH),  6.42 (1H, t, J = 6.4 Hz, OCHN),  
6.96 (2H, p, J = 7.6 and 8.7 Hz, ArH), 7.18-7.44 (7H, overlapping m, ArH), 7.72 (1H, d, J = 7.6 
Hz, ArH) and 7.87 (1H, s, ArH); δC (100 MHz; CD3OD) 12.5 (CH3Ar), 39.0 (CH2CHN), 44.6 
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and 48.8 (CH2N), 52.2 (OCH3), 54.1 (CHCO), 60.8 (CHN), 62.1 (CH2OH), 68.7 (CHOH), 71.1 
(OCH2Ph), 86.3 (HOCH2CHO), 86.6 (NCHO), 111.7, 113.0, 122.0, 123.7, 123.8, 128.3, 128.5, 
128.9, 129.6, 129.8, 132.0, 138.2, 138.6, 147.0, 147.1, 152.2, 156.8, 166.4 and 175.6 (Ar-C, C=C 
and C=O). 
 
3.3. PREPARATION of NON-BENZYLATED 3-HYDROXYPROPANOATE ESTER-
AZT CONJUGATES 
tert-Butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 113a 
 
A mixture of 5-bromosalicylaldehyde (8.2 g, 41 mmol), tert-butyl acrylate (9 mL, 60 mmol) and 
DABCO (3.4 g, 30 mmol) in CHCl3 (12 mL) was stirred at room temperature for 7 days after 
which the crude product was filtered and washed with CHCl3 to afford tert-butyl 3-(5-bromo-2-
hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 113a as a white solid (9.3 g, 69%), m.p. 180-
182 oC (lit.119 186-188 oC); ʋmax/cm-1 3290 (OH) and 1683 (C=O); δH (400 MHz;  DMSO-d6) 131 
[9H, s, C(CH3)3], 5.64 (1H, s, CHOH), 5.66 and 6.05 (2H, 2 x s, C=CH2), 6.75 (1H, d, J = 8.5 
Hz, ArH), 7.17-7.24 (2H, overlapping m, ArH); δC (100 MHz; DMSO-d6) 27.6 [C(CH3)3], 64.6 
(CHOH), 80.1 [C(CH3)3], 109.7 and 117.2 (Ar-C), 123.1 (C=CH2), 129.8, 130.5 and 132.0 (Ar-
C), 144.9 (C=CH2), 153.9 [ArC(OH)] and 165.0 (C=O). 
tert-Butyl 3-(5-chloro-2-hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 113b 
 
The procedure described for the synthesis of tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-
hydroxy-2-methylenepropanoate 113a was employed using 5-chlorosalicylaldehyde (6.4 g, 41 
mmol), tert-butyl acrylate (9 mL, 60 mmol) and DABCO 93.4 g, 30 mmol) in CHCl3 (12 mL). 
Work-up afforded tert-butyl 3-(5-chloro-2-hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 
113b as a white solid (6.3 g, 54%), m.p. 166-168 oC (lit.135 185-187 oC); ʋmax/cm-1 3350 (OH) 
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and 1683 (C=O); δH (400 MHz;  DMSO-d6) 131 [9H, s, C(CH3)3], 5.67 (1H, s, CHOH), 5.64 and 
6.05 (2H, 2 x s, C=CH2), 6.79 (1H, d, J = 8.5 Hz,  ArH), 7.05-7.11 (2H, overlapping m, ArH); δC 
(100 MHz; DMSO-d6) 27.6 [C(CH3)3], 64.6 (CHOH), 80.1 [C(CH3)3], 116.6 and 122.1 (Ar-C), 
123.1 (C=CH2), 126.9, 127.6 and 131.4 (Ar-C), 144.9 (C=CH2), 153.4 [ArC(OH)] and 165.0 
(C=O). 
tert-Butyl 3-hydroxy-3-(2-hydroxphenyl)-2-methylenepropanaoate 113c 
 
A mixture of salicylaldehyde (4.3 mL, 41 mmol), tert-butyl acrylate (9 mL, 60 mmol) and 
DABCO (3.4 g, 30 mmol) in CHCl3 (12 mL) was stirred at room temperature for 30 days after 
which the crude product was concentrated under vacuum and purified by column 
chromatography [on silica gel; elution with hexane-EtOAc (4:1)] to afford tert-butyl 3-hydroxy-
3-(2-hydroxphenyl)-2-methylenepropanaoate 113c as a white solid (3.7 g, 36%), m.p. 98-100 oC 
(lit.119 108-110 oC); ʋmax/cm-1 3350 (OH) and 1687 (C=O); δH (400 MHz; CD3OD) 1.33 [9H, s, 
C(CH3)3], 5.76 and 6.17 (2H, 2 x s, C=CH2) , 5.89 (1H, d, J = 3.7 Hz, CHOH),  6.75-6.78 (2H, 
m, ArH), 7.05-7.12 (2H, overlapping m, ArH); δC (100 MHz; CD3OD) 28.13 [C(CH3)3], 67.85 
(CHOH), 82.1 [C(CH3)3], 116.3 and 120.2 (Ar-C), 123.6 (C=CH2), 128.6, 129.3 and 129.7 (Ar-
C), 146.3 (C=CH2), 156.3 [ArC(OH)] and 167.4 (C=O).  
tert-Butyl 3-hydroxy-3-(2-hydroxy-3-methoxyphenyl)-2-methylenepropanoate 113d122 
 
The procedure described for the synthesis of tert-butyl 3-hydroxy-3-(2-hydroxphenyl)-2-
methylenepropanaoate 113c was followed using 3-methoxysalicylaldehyde (6.2  g, 41 mmol), 
tert-butyl acrylate (9 mL, 60 mmol) and DABCO (3.4 g, 30 mmol) in CHCl3 (12 mL). Work-up 
afforded tert-butyl 3-hydroxy-3-(2-hydroxy-3-methoxyphenyl)-2-methylenepropanoate 113d as 
a yellow oil (3.0 g, 26%); ʋmax/cm-1 3428 (OH) and 1706 (C=O); δH (400 MHz; CDCl3) 1.44 
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[9H, s, C(CH3)3], 5.65 and 6.22 (2H, 2 x s, C=CH2), 3.85 (3H,s, OCH3) 5.80 (1H, d, J = 4.9 Hz, 
CHOH), 6.80 (3H, d, J = 3.9 Hz, ArH); δC (100 MHz; CDCl3) 27.9 [C(CH3)3], 56.0 (OCH3) 69.7 
(CHOH), 81.7 [C(CH3)3], 110.4, 119.5 and 119.6 (Ar-C), 125.3 (C=CH2), 126.3 (Ar-C), 141.9 
(C=CH2), 143.6 [ArC(OH)], 147.0 [ArC(OMe)] and 166.1 (C=O). 
tert-Butyl 3-(3-ethoxy-2-hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 113e122 
 
The procedure described for the synthesis of tert-butyl 3-hydroxy-3-(2-hydroxphenyl)-2-
methylenepropanaoate 113c was followed using 3-methoxysalicylaldehyde (6.8  g, 41 mmol), 
tert-butyl acrylate (9 mL, 60 mmol) and DABCO (3.4 g, 30 mmol) in CHCl3 (12 mL). Work up 
afforded tert-butyl 3-(3-ethoxy-2-hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 113e as a 
yellow oil (2.5 g, 21%); ʋmax/cm-1 3417 (OH) and 1699 (C=O); δH (400 MHz; CDCl3) 1.34-1.48 
[12H, m, overlapping s and t, C(CH3)3 and CH2CH3], 4.09 (2H, dt, J = 6.8 and 13.4 Hz, 
OCH2CH3), 5.66 and 6.21 (2H, 2 x s, C=CH2) , 5.81 (1H, d, J = 5.2 Hz, CHOH),  6.80 (3H, 
overlapping m, ArH); δC (100 MHz; CDCl3) 14.7 (CH2CH3), 27.9 [C(CH3)3], 64.8 (OCH2CH3) 
69.3 (CHOH), 81.5 [C(CH3)3], 111.2, 119.2 and 119.5 (Ar-C), 125.1 (C=CH2), 126.5 (Ar-C), 
142.1 (C=CH2), 143.6 [ArC(OH)], 146.0 [ArC(OEt)] and 166.0 (C=O). 
tert-Butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 
114a 
OH
OBut
OH O
Br
N
H  
To a solution of tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 
113a (0.72 g, 2.2 mmol) in dry THF (3 mL) was added propargylamine (0.3 mL, 4 mmol) and 
the mixture stirred at r.t. for 3 days. The mixture was then concentrated under vacuum and 
column chromatographed [on silica gel; elution with hexane-EtOAc (2:1) to afford tert-butyl 3-
(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 114a as a white 
solid (0.65 g, 77%), m.p. 136-138 oC (lit.122 136-138 oC); ʋmax/cm-1 3265 (OH) and 1729 (C=O); 
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δH (400 MHz; CD3OD) 1.32 [9H, s, C(CH3)3], 2.54 (1H, s, C≡CH ), 2.85 (1H, s, CHCHa), 2.95 
(1H, d, J = 6.2 Hz, CHCHb), 3.03 (1H, t, J = 6.2 Hz, CHCO),  3.30 (2H, d, J = 5.0 Hz, 
CH2C≡CH), 5.16 (1H, d, J = 6.4 Hz, CHOH), 6.65 (1H, d, J = 6.7 Hz, ArH), 7.18 (1H, d, J = 8.7 
Hz, ArH) and 7.37 (1H, d, J = 4.8 Hz, ArH); δC (100 MHz; CD3OD), 28.2 [C(CH3)3], 38.5 and 
47.9 (NCH2), 52.1 (CHCO), 71.2 (CHOH), 73.4 and 81.8 (C≡CH), 82.2 [C(CH3)3], 112.0, 118.2, 
131.8, 131.9 and 132.1 (Ar-C), 155.1 [ArC(OH)] and 173.5 (C=O). 
tert-Butyl 3-(5-chloro-2-hydroxyphenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 
114b 
OH
OBut
OH O
Cl
N
H   
The procedure for the synthesis of tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-[(2-
propynylamino)methyl]propanoate 114a was followed using tert-butyl 3-(5-chloro-2-
hydroxyphenyl)-3-hydroxy-2-methylenepropanoate 113b (0.63 g, 2.2 mmol), dry THF (3 mL), 
and propargylamine (0.3 mL, 4 mmol). Work-up afforded tert-butyl 3-(5-chloro-2-
hydroxyphenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 114b as a white solid (0.63, 
84%), m.p. 118-120 oC (lit.122 125-126 oC); ʋmax/cm-1 3464 (OH) and 1693 (C=O); δH (400 MHz;  
CD3OD) 1.30 [9H, s, C(CH3)3], 2.52 (1H, s, C≡CH ), 2.84 (1H, d, J = 6.8 Hz, CHCHa), 2.94 
(1H, s, CHCHb), 3.02 (1H, t, J = 6.1 Hz, CHCO), 3.29 (2H, d, J = 4.9 Hz, CH2C≡CH), 5.15 (1H, 
d, J = 7.1 Hz, CHOH), 6.7 (1H, t, J = 6.5 Hz, ArH), 7.02 (1H, tt, J = 2.9 and 5.9 Hz, ArH) and 
7.23 (1H, t, J = 3.7 Hz, ArH); δC (100 MHz; CD3OD), 28.2 [C(CH3)3], 38.5 and 47.9 (NCH2), 
52.0 (CHCO), 71.2 (CHOH), 73.4 and 81.7 (C≡CH), 82.2 [C(CH3)3], 117.7, 125.0, 128.8, 129.1 
and 131.4 (Ar-C), 154.6 [ArC(OH)] and 173.5 (C=O). 
tert-Butyl 3-hydroxy-3-(2-hydroxphenyl)-2-[(propynylamino)methyl]propanaoate 114c 
 
The procedure for the synthesis of tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-[(2-
propynylamino)methyl]propanoate 114a was followed using tert-butyl 3-hydroxy-3-(2-
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hydroxphenyl)-2-methylenepropanaoate 113c (0.55 g, 2.2 mmol),  dry THF (3 mL), and 
propargylamine (0.3 mL, 4 mmol). Work-up afforded tert-butyl 3-hydroxy-3-(2-hydroxphenyl)-
2-[(propynylamino)methyl]propanaoate 114c as a white solid (0.36 g, 57%), m.p. 66-68 oC 
(lit.122 68-70 oC); ʋmax/cm-1 3460 (OH) and 1710 (C=O); δH (400 MHz; CD3OD) 1.29 [9H, s, 
C(CH3)3], 2.56 (1H, s, C≡CH ), 2.90-3.00 (2H, m, CHCH2), 3.09 (1H, t, J = 6.1 Hz, CHCO),  
3.29 (2H, d, J =16.3 Hz, CH2C≡CH), 5.16-5.23 (1H, m, CHOH), 6.8 (2H, dd, J = 5.32 and 14.7 
Hz, ArH), 7.06 (1H, d, J = 6.1 Hz, ArH) and 7.31 (1H, d, J = 6.8 Hz, ArH); δC (100 MHz; 
CD3OD), 28.2 [C(CH3)3], 38.5 and 48.2 (NCH2), 52.2 (CHCO), 72.2 (CHOH), 73.5 and 81.6 
(C≡CH), 82.1 [C(CH3)3], 116.3, 125.8, 129.0, 129.6 and 132.6 (Ar-C), 155.9 [ArC(OH)] and 
173.7 (C=O). 
tert-Butyl 3-hydroxy-3-(2-hydroxy-3-methoxyphenyl)-2-[(2-propynylamino)methyl]propanoate 
114d 
 
The procedure for the synthesis of tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-[(2-
propynylamino)methyl]propanoate 114a was followed using tert-butyl 3-hydroxy-3-(2-hydroxy-
3-methoxyphenyl)-2-methylenepropanoate 113d (0.62 g, 2.2 mmol), dry THF (3 mL), and 
propargylamine (0.3 mL, 4 mmol). Work-up afforded tert-butyl 3-hydroxy-3-(2-hydroxy-3-
methoxyphenyl)-2-[(2-propynylamino)methyl]propanoate 114d as a yellow oil (0.5 g, 67%); 
ʋmax/cm-1 3301 (OH) and 1715 (C=O); δH (400 MHz; CD3OD) 1.30 [9H, s, C(CH3)3], 2.55 (1H, 
s, C≡CH ), 2.94 (2H, qt, J = 6.3 and 12.9 Hz, CHCH2), 3.04-3.10 (1H, m, CHCO), 3.26-3.33 
(2H, m, CH2C≡CH), 3.82 (3H, s, OCH3), 5.28 (1H, s, CHOH), 6.77 (1H, d, J = 7.1 Hz, ArH), 
6.83 (1H, d, J = 7.0 Hz, ArH) and 6.91 (1H, d, J = 7.3 Hz, ArH); δC (100 MHz; CD3OD), 28.2 
[C(CH3)3], 38.6 and 48.1 (NCH2), 52.3 (CHCO), 56.5 (OCH3), 71.4 (CHOH), 73.4 and 81.8 
(C≡CH), 82.0 [C(CH3)3], 111.5, 119.9, 120.8 and 129.5 (Ar-C), 144.8 and 148.7 [ArC(OH) and 
ArC(OMe)] and 173.7 (C=O). 
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tert-Butyl 3-(3-ethoxy-2-hydroxyphenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 
114e122 
 
The procedure for the synthesis of tert-butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-[(2-
propynylamino)methyl]propanoate 114a was followed tert-butyl 3-(3-ethoxy-2-hydroxyphenyl)-
3-hydroxy-2-methylenepropanoate 113e (0.65 g, 2.2 mmol), dry THF (3 mL), and 
propargylamine (0.3 mL, 4 mmol). Work up afforded tert-butyl 3-(3-ethoxy-2-hydroxyphenyl)-3-
hydroxy-2-[(2-propynylamino)methyl]propanoate 114e as a yellow oil (0.36 g, 46%); ʋmax/cm-1 
3285 (OH) and 1714 (C=O); δH (400 MHz; CD3OD) 1.31 [9H, s, C(CH3)3], 1.38 (3H,d, J = 6.2 
Hz, OCH2CH3),  2.56 (1H, s, C≡CH ), 2.94 (2H, dd,  J = 6.7 and 12.7 Hz, CHCH2), 3.08 (1H, t, J 
= 6.3 Hz, CHCO), 3.28-3.32 (2H, m, CH2C≡CH), 4.06 (2H, t, J = 6.7 Hz, OCH2), 5.27 (1H, s, 
CHOH), 6.75 (1H, d, J = 7.1 Hz, ArH), 6.81 (1H, d, J = 5.9 Hz, ArH) and 6.90 (1H, d, J = 6.3 
Hz, ArH); δC (100 MHz; CD3OD), 15.1 (OCH2CH3) 28.2 [C(CH3)3], 38.5 and 48.1 (NCH2), 52.2 
(CHCO),6 5.6 (OCH2), 71.5 (CHOH), 73.4 and 81.7 (C≡CH), 82.0 [C(CH3)3], 112.8, 119.9, 
120.8 and 129.5 (Ar-C), 145.0 and 147.8 [ArC(OH) and ArC(OEt)] and 173.7 (C=O). 
3-Hydroxypropanoate ester-AZT conjugate 115a 
 
tert-Butyl 3-(5-bromo-2-hydroxyphenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 
114a (0.15 g, 0.4 mmol) was dissolved in CH3CN (2 mL) and 3`-azidodeoxythymidine (0.12 g, 
0.44 mmol), Et3N (67 µL) and CuI (0.008 g) were added to the solution. The mixture was stirred 
for 48 hours then diluted with DCM (10 mL), washed with saturated aq. NH4Cl solution (5 mL), 
followed by brine (5 mL), and dried over magnesium sulfate. The organic solution was 
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concentrated under vacuum and the crude product purified by column chromatography [on silica 
gel; elution with hexane-EtOAc (2:1)] to afford 3-Hydroxypropanoate ester-AZT conjugate 115a 
as a pale yellow oil (0.32 g, 13%); [HMRS: m/z calculated for C27H36BrN6O8 (MH+) 651.1778. 
Found 651.1790]; ʋmax/cm-1 1683 (C=O); δH (400 MHz; CD3OD) 1.30 [9H, s, C(CH3)3], 1.86 
(3H, s, CH3), 2.68 (1H, dd, J = 7.1 and 13.7 Hz, CHaCHN), 2.75-2.88 (2H, m, CHCHaN and 
CHbCHN), 2.89-2.95 (1H, m, CHCHbN), 3.02 (1H, q, J = 11.36 and 14.7 Hz, CHCO), 3.73 and 
3.79 (2H, s, CH2CN), 3.86 (2H, d, J = 12.6 Hz, CH2OH), 4.30 (1H, s, OCHCHN), 5.15 (1H, s, 
CHOH), 5.36 (1H, s, OCHCH2OH), 6.44 (1H, q, J = 5.6 Hz, OCHN),  6.62-6.88 (1H, m, ArH), 
7.12-7.20 (1H, m, ArH) 7.35 (1H, d, J = 10.0 Hz, ArH) 7.89 (2H, dd, J = 5.4 and 14.4 Hz, ArH); 
δC (100 MHz; CD3OD) 12.5 (CH3Ar), 28.2 [C(CH3)3], 39.1 (CH2CHN), 44.8 and 48.0 (CH2N), 
52.0 (CHCO),  60.9 (CHN), 62.1 (CH2OH), 71.1 (CHOH), 82.2 [C(CH3)3], 86.4 (HOCH2CHO), 
86.7 (NCHO), 111.6, 112.0, 118.2, 123.9, 131.7, 131.8, 132.0, 132.1, 138.3, 152.3, 155.1, 166.4 
and 173.5 (Ar-C, C=C and C=O). 
3-Hydroxypropanoate ester-AZT conjugate 115b 
 
The procedure described for the synthesis of 115a was followed using tert-butyl 3-(5-chloro-2-
hydroxyphenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 114b (0.14 g, 0.4 mmol), 
CH3CN (1 mL) and 3`-azidodeoxythymidine (0.12 g, 0.44 mmol), Et3N (67 µL) and CuI (0.008 
g). Work-up afforded 3-hydroxypropanoate ester-AZT conjugate 115b as a pale yellow solid 
(0.036 g, 14%), m.p. 100-102 oC; [HMRS: m/z calculated for C27H36ClN6O8 (MH+) 607.0610. 
Found 607.1104]; ʋmax/cm-1 1683 (C=O); δH (400 MHz; CD3OD) 1.29  [9H, s, C(CH3)3], 1.84 
(3H, s, CH3), 2.58-2.97 (4H, m, CH2CHN, and CHCH2N), 3.03 (1H, s, CHCO), 3.60-3.94 (4H, 
m, CH2CN and CH2OH), 4.29 (1H, s, OCHCHN), 5.15 (1H, s, CHOH), 5.36 (1H, s, 
OCHCH2OH), 6.42 (1H, s, OCHN), 6.63 (1H, d, J = 8.3 Hz, ArH), 7.17 (1H, dd, J = 8.5 and 
25.3 Hz, ArH) 7.33 (1H, s, ArH), 7.67-8.05 (2H, m, ArH); δC (100 MHz; CD3OD) 12.5 (CH3Ar), 
28.2 [C(CH3)3], 39.1 (CH2CHN), 44.8 and 48.2 (CH2N), 52.0 (CHCO), 60.9 (CHN), 62.1 
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(CH2OH), 71.1 (CHOH), 82.2 [C(CH3)3], 86.4 (HOCH2CHO), 86.6 (NCHO), 111.6, 118.3, 
119.3, 124.0, 131.7, 132.1, 135.1, 138.2, 140.1, 152.2, 155.1, 166.4 and 173.5 (Ar-C, C=C and 
C=O). 
3-Hydroxypropanoate ester-AZT conjugate 115c 
 
The procedure described for the synthesis of 115a was followed using tert-butyl 3-hydroxy-3-(2-
hydroxphenyl)-2-[(propynylamino)methyl]propanaoate 114c (0.10 g, 0.4 mmol), CH3CN (1 mL) 
and 3`-azidodeoxythymidine (0.12 g, 0.44 mmol), Et3N (67 µL) and CuI (0.008 g). Work-up 
afforded 3-Hydroxypropanoate ester-AZT conjugate 115c as a pale yellow oil (0.030 g, 16%); 
[HMRS: m/z calculated for C27H36N6O8 (MH+) 573.2673. Found 573.2676]; ʋmax/cm-1 1683 
(C=O);  δH (400 MHz;  CD3OD) 1.32  [9H, s, C(CH3)3], 1.86 (3H, s, CH3), 2.67 (1H, td, J = 4.1 
and 8.1 Hz, CHaCHN), 2.82 (2H, dt, J = 6.1 and 12.5 Hz, CHCHaN and CHbCHN), 2.91 (1H, t, J 
= 9.8 Hz, CHCHbN), 3.08 (1H, q, J = 6.1 Hz, CHCO), 3.73 (2H, s, CH2CN), 3.88 (2H, s, 
CH2OH), 4.23-4.34 (1H, m, OCHCHN), 5.27 (1H, dt, J = 5.3 and 10.2 Hz, CHOH), 5.33-5.39 
(1H, m, OCHCH2OH), 6.44 (1H, q, J = 6.5 Hz, OCHN),  7.30 (2H, dt, J = 3.2 and 7.4 Hz, ArH), 
7.48-7.62 (2H, m, ArH), 7.84-7.94 (2H, m, ArH); δC (100 MHz; CD3OD) 12.5 (CH3Ar), 28.2 
[C(CH3)3], 39.0 (CH2CHN), 44.2 and 48.8 (CH2N), 51.2 (CHCO), 61.0 (CHN), 62.1 (CH2OH), 
71.9 (CHOH), 82.4 [C(CH3)3], 86.4 (HOCH2CHO), 86.6 (NCHO), 111.7, 117.2, 120.6, 125.9, 
129.3, 132.6, 138.2, 142.0, 152.3, 154.6, 163.1, 166.4 and 173.5 (Ar-C, C=C and C=O). 
3-Hydroxypropanoate ester-AZT conjugate 115d 
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The procedure described for the synthesis of 115a was followed using tert-butyl 3-hydroxy-3-(2-
hydroxy-3-methoxyphenyl)-2-[(2-propynylamino)methyl]propanoate 114d (0.13 g, 0.4 mmol), 
CH3CN (1 mL) and 3`-azidodeoxythymidine (0.12 g, 0.44 mmol), Et3N (67 µL) and CuI (0.008 
g). Work-up afforded 3-Hydroxypropanoate ester-AZT conjugate 115d as a pale yellow oil (0.16 
g, 66%); [HMRS: m/z calculated for C28H39N6O9 (MH+) 603.2779. Found 603.2783]; ʋmax/cm-1 
1683 (C=O); δH (400 MHz; CD3OD) 1.30 [9H, s, C(CH3)3], 1.87 (3H, s, CH3), 2.69 (1H, td, J = 
4.4 and 8.4 Hz, CHaCHN), 2.77-2.85 (2H, m, CHCHaN and CHbCHN), 2.91 (1H, t, J = 9.8 Hz, 
CHCHbN), 3.08 (1H, q, J = 6.1 Hz, CHCO), 3.73 and 3.85 (2H, s, CH2CN), 3.76-3.84 (5H, s, 
OCH3 and CH2OH), 4.23-4.34 (1H, m, OCHCHN), 5.27 (1H, d, J = 6.1 Hz, CHOH), 5.33-5.39 
(1H, m, OCHCH2OH), 6.44 (1H, t, J = 6.4 Hz, OCHN),  6.71-6.88 (2H, m, ArH), 7.89 (2H, q, J 
= 5.4 Hz, ArH); δC (100 MHz; CD3OD) 12.5 (CH3Ar), 28.2 [C(CH3)3], 39.1 (CH2CHN), 44.7 
and 48.1 (CH2N), 51.9 (CHCO), 56.6 (OCH3), 60.9 (CHN), 62.1 (CH2OH), 71.4 (CHOH), 82.1 
[C(CH3)3], 86.4 (HOCH2CHO), 86.7 (NCHO), 111.5, 111.7, 119.9, 120.6, 124.1, 129.5, 138.3, 
144.7, 146.7, 148.7, 152.3, 166.4 and 173.8 (Ar-C, C=C and C=O). 
3-Hydroxypropanoate ester-AZT conjugate 115e 
 
The procedure described for the synthesis of 115a was followed using tert-butyl 3-(3-ethoxy-2-
hydroxyphenyl)-3-hydroxy-2-[(2-propynylamino)methyl]propanoate 114e (0.18 g, 0.4 mmol), 
CH3CN (1 mL) and 3`-azidodeoxythymidine (0.12 g, 0.44 mmol), Et3N (67 µL) and CuI (0.008 
g). Work-up afforded 3-Hydroxypropanoate ester-AZT conjugate 115e as a pale yellow oil (0.30 
g, 10%); [HMRS: m/z calculated for C29H41N6O9 (MH+) 617.2935. Found 617.2956]; ʋmax/cm-1 
1682 (C=O); δH (400 MHz; CD3OD) 1.32  [9H, s, C(CH3)3], 1.35 (3H, t, J = 6.9 Hz, OCH2CH3), 
1.86 (3H, s, CH3), 2.68 (1H, ddd, J = 6.1, 8.6 and 14.3 Hz, CHaCHN), 2.82 (2H, q, J = 4.5 and 
5.5 Hz, CHCHaN and CHbCHN), 2.85-2.92 (1H, m, CHCHbN), 3.07 (1H, td, J = 4.8 and 7.0 Hz, 
CHCO), 3.65-3.79 (2H, m, CH2CN), 3.81-3.90 (2H, m, CH2OH), 3.99-4.07 (2H, m, OCH2CH3), 
4.30 (1H, dt, J = 3.0 and 5.7 Hz, OCHCHN), 5.25 (1H, d, J = 6.2 Hz, CHOH), 5.31-5.38 (1H, m, 
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OCHCH2OH), 6.43 (1H, t, J = 6.4 Hz, OCHN),  6.71 (1H, t, J = 7.9 Hz, ArH), 6.79(1H, dd, J = 
1.6 and 8.1 Hz, ArH), 6.84 (1H, dd, J = 1.6 and 7.7 Hz, ArH), 7.88 (2H, dd,  J = 6.1 and 11.9 Hz, 
ArH); δC (100 MHz; CD3OD) 12.5 (CH3Ar), 15.1 (CH2CH3), 28.2 [C(CH3)3], 39.0 (CH2CHN), 
44.8 and 48.2 (CH2N), 52.0 (CHCO), 60.9 (CHN), 62.1 (CH2OH), 65.6 (OCH2CH3), 71.5 
(CHOH), 82.0 [C(CH3)3], 86.4 (HOCH2CHO), 86.7 (NCHO), 111.6, 112.7, 119.9, 120.6, 124.0, 
129.6, 138.3, 144.9, 146.9, 147.8, 152.3, 166.4 and 173.8 (Ar-C, C=C and C=O). 
 
3.4. 4-SUBSTITUTED COUMARINS 
Methyl (Z)-3-[2-(benzyloxy)-5-bromophenyl]-2-(bromomethyl)-2-propenoate 116a 
O
O
OBn
Br
Br  
To a cooled mixture of methyl 3-(2-benzyloxy-5-bromophenyl)-3-hydroxy-2-
methylenepropanoate 106a (0.4 g, 1mmol) in acetonitrile (5 mL) was added conc. H2SO4 (1.5 
mL) and LiBr (0.34 g, 4 mmol) and the mixture was stirred at 0 oC for 30 minutes and allowed to 
warm up to r.t. and then stirred further for 4 h. The mixture was then diluted in DCM, washed 
with water (15 mL), saturated aq. NaHCO3 (15 mL) and brine (15 mL), dried over MgSO4 and 
finally concentrated under vacuum and column chromatographed [on silica gel; elution with 
hexane-EtOAc (1:1)] affording methyl (Z)-3-[2-(benyloxy)-5-bromophenyl]-2-(bromomethyl)-2-
propenoate 116a as a yellow solid (0.4g, 86%), m.p. 87-90 oC (lit.122 90-91 oC); ʋmax/cm-1 1700 
(C=O); δH (400 MHz; CDCl3) 3.87 (3H, s, OCH3), 4.33 (2H, s, CH2Br), 5.12 (2H, s, OCH2Ph), 
6.84 (1H, d, J = 8.8 Hz, ArH), 7.31-7.44 (6H overlapping m, ArH), 7.81 (1H, d, J = 2.4 Hz, 
ArH), 7.96 (1H, s, 1`-H); δC (100 MHz; CDCl3) 26.6 and 70.6 (CH2), 52.5 (OCH3), 113.2, 114.2, 
125.8, 127.0, 128.2, 128.7, 129.6, 131.9, 133.6, 136.0 and 137.3 (C=CH and Ar-C), 156.0 
[ArC(OBn)] and 166.0 (C=O). 
Methyl (Z)-3-[2-(benzyloxy)-5-chlorophenyl]-2-(bromomethyl)-2-propenoate 116b 
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The procedure described for the synthesis of methyl (Z)-3-[2-(benzyloxy)-5-bromophenyl]-2-
(bromomethyl)-2-propenoate 116a was followed using methyl 3-(2-benzyloxy-5-chlorophenyl)-
3-hybroxy-2-methylenepropanoate 106b (0.33 g, 1 mmol), conc. H2SO4 (1.5 mL) and LiBr (0.34 
g, 4 mmol) in acetonitrile (5 mL). Work-up afforded methyl (Z)-3-[2-(benyloxy)-5-
chlorophenyl]-2-(bromomethyl)-2-propenoate 116b as a yellow solid (0.4 g, 84%), m.p.76-78 oC 
(lit.122 80-81 oC); ʋmax/cm-1 1714 (C=O); δH (400 MHz; CDCl3) 3.87 (3H, s, OCH3), 4.33 (2H, s, 
CH2Br), 5.12 (2H, s, OCH2Ph), 6.89 (1H, d, J = 8.9 Hz, ArH), 7.28-7.39 (6H overlapping m, 
ArH), 7.68 (1H, d, J = 2.5 Hz, ArH), 7.97 (1H, s, 1`-H); δC (100 MHz; CDCl3) 26.6 and 70.7 
(CH2), 52.5 (OCH3), 113.8, 125.33, 126.0, 127.0, 128.2, 128.7, 129.6, 130.6, 137.4, 136.0 and 
137.4 (C=CH and Ar-C), 155.5 [ArC(OBn)] and 166.3 (C=O). 
Methyl (Z)-3-[2-(benzyloxy)phenyl]-2-(bromomethyl)-2-propenoate 116c122 
 
The procedure described for the synthesis of methyl (Z)-3-[2-(benyloxy)-5-bromophenyl]-2-
(bromomethyl)-2-propenoate 116a was followed using methyl 3-(2-benzyloxyphenyl)-3-
hydroxy-2-methylenepropanoate 106c (0.4 g, mmol), conc. H2SO4 91.5 mL) and LiBr (0.34 g, 4 
mmol) in acetonitrile (5 mL). Work-up afforded methyl (Z)-3-[2-(benyloxy)phenyl]-2-
(bromomethyl)-2-propenoate 116c as a colourless gel (0.29g, 55%); ʋmax/cm-1 1712 (C=O); δH 
(400 MHz; CDCl3) 3.87 (3H, s, OCH3), 4.39 (2H, s, CH2Br), 5.15 (2H, s, OCH2Ph), 6.97 (1H, d, 
J = 8.3 Hz, ArH), 7.07 (1H, t, J = 7.4 Hz, ArH), 7.33-7.41 (6H overlapping m, ArH), 7.72 (1H, 
d, J = 7.5 Hz) and 8.11 (1H, s, 1`-H); δC (100 MHz; CDCl3) 27.4 and 70.3 (CH2), 52.3 (OCH3), 
112.5, 121.0, 123.9, 127.0, 128.4, 128.6, 129.6, 131.1, 136.5 and 138.9 (C=CH and Ar-C), 157.1 
[ArC(OBn)] and 166.7 (C=O). 
Methyl 3-[2-(benzyloxy)-5-bromophenyl]-3-phthalimido-2-methylenepropanoate 117a122 
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To a solution of methyl (Z)-3-[2-(benzyloxy)-5-bromophenyl]-2-(bromomethyl)-2-propenoate 
116a (0.25 g, 0.57 mmol) in CH3CN (3 mL) was added DABCO (0.08 g, 0.7 mmol) and the 
mixture stirred for 30 minutes after which potassium phthalimide (0.12 g, 0.65 mmol) was added 
and the mixture stirred at r.t. for 2 days. The crude mixture was concentrated under vacuum and 
chromatographed [PLC on silica gel; elution with hexane-EtOAc (3:1) afforded methyl 3-[2-
(benzyloxy)-5-bromophenyl]-3-phthalimido-2-methylenepropanoate 117a as a cream gel (0.24 g, 
84%); [HRMS: m/z calculated for C26H21BrNO5 (MH+) 506.0603. Found 506.0594]; ʋmax/cm-1 
1709 (C=O); δH (400 MHz; CDCl3) 3.69 (3H, s, OCH3), 5.04 (2H, s, OCH2PH), 5.68 and 6.56 
(2H, 2 x s, C=CH2), 6.77 (1H, d, J = 8.7 Hz, ArH) 6.79 (1H, s, CHN), 7.24-7.29 (5H, 
overlapping m, ArH), 7.33 (1H, dd, J = 2.6 and 8.7 Hz, ArH), 7.46 (1H, d, J = 2.5 hz, ArH), 7.70 
(2H, dd, J = 3.0 and 5.5 Hz, ArH) and 7.79 (2H, dd, J = 3.0 and 5.5 Hz, ArH); δC (100 MHz; 
CDCl3) 48.8 (CHN),52.2 (OCH3), 70.3 (CH2), 113,0, 113.7, 123.4, 127.1, 127.7, 127.9, 128.4, 
129.1, 132.0, 132.1, 134.0, 136.1 and 136.4 (C=CH and Ar-C),154.6 [ArC(OBn)], 165.8 and 
167.8 (C=O). 
Methyl 3-[2-(benzyloxy)-5-chlorophenyl]-3-phthalimido-2-methylenepropanoate 117b 
O
CO2Me
N
Cl
OO
Bn  
The procedure described for the synthesis of methyl 3-[2-(benzyloxy)-5-bromophenyl]-3-
phthalimido-2-methylenepropanoate 117a was followed using methyl (Z)-3-[2-(benyloxy)-5-
chlorophenyl]-2-(bromomethyl)-2-propenoate 116b (0.23 g, 0.57 mmol), CH3CN (3 mL), 
DABCO (0.08 g, 0.7 mmol) and potassium phthalimide (0.12 g, 0.65 mmol). Work-up afforded 
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methyl 3-[2-(benzyloxy)-5-chlorophenyl]-3-phthalimido-2-methylenepropanoate 117b as a 
cream gel (0.21 g, 79%); [HRMS: m/z calculated for C26H21ClNO5 (MH+) 462.1108. Found 
462.1102]; ʋmax/cm-1 1710 (C=O); δH (400 MHz; CDCl3) 3.69 (3H, s, OCH3), 5.05 (2H, s, 
OCH2PH), 5.69 and 6.57 (2H, 2 x s, C=CH2), 6.80 (1H, s, CHN), 6.83 (1H,d, J = 8,7 Hz, ArH), 
7.19 (!H, dd, J = 2.6 and 8.7 Hz, ArH) 7.25-7.28 (5H, overlapping m, ArH), 7.34 (1H, d, J = 2.6 
Hz, ArH), 7.70 (2H, dd, J = 3.0 and 5.5 Hz, ArH) and 7.80 (2H, dd, J = 3.0 and 5.5 Hz, ArH); δC 
(100 MHz; CDCl3) 48.9 (CHN), 52.2 (OCH3), 70.4 (CH2), 113,2, 123.4, 125.7, 127.2, 127.3, 
127.9, 128.4, 129.0, 129.3, 131.7, 134.0, 136.1 and 136.4 (C=CH and Ar-C), 154.2 
[ArC(OBn)],165.8 and 167.8 (C=O). 
 
Methyl 3-(2-benzyloxyphenyl)-3-phthalimido-2-methylenepropanoate 117c 
 
The procedure described for the synthesis of methyl 3-[2-(benzyloxy)-5-bromophenyl]-3-
phthalimido-2-methylenepropanoate 117a was followed using methyl (Z) 3-(2-
benzyloxyphenyl)-3-hydroxy-2-methylpropanoate 116c (0.1 g, 0.28 mmol), CH3CN (1.5 mL), 
DABCO (0.04 g, 0.35 mmol) and potassium phthalimide (0.06 g, 0.33 mmol). Work-up afforded 
methyl 3-(2-benzyloxyphenyl)-3-phthalimido-2-methylenepropanoate 117c as a cream oil (0.1 g, 
86%); [HRMS: m/z calculated for C26H22NO5 (MH+) 428.1498. Found 428.1477]; ʋmax/cm-1 1708 
(C=O); δH (400 MHz;  CDCl3)  3.66 (3H, s, OCH3), 5.06 (2H, s, OCH2PH), 5.65 and 6.53 (2H, 2 
x s, C=CH2), 6.85 (1H, s, CHN), 6.91 (2H, m, ArH) 7.19-7.29 (6H, overlapping m, ArH), 7.37 
(1H, t, J = 6,3 Hz, ArH), 7.66 (2H, s, ArH) and 7.76 (2H, s, ArH) δC (100 MHz; CDCl3) 49.2 
(CHN),52.1 (OCH3), 70.0 (CH2), 111.9, 120.6, 123.3, 125.4, 127.2, 127.7, 128.4, 128.6, 129.2, 
129.3, 131.8, 133.9, 136.7 and 137.0 (C=CH and Ar-C),155.6 [ArC(OBn)], 166.1 and 167.9 
(C=O). 
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4-Phthalimido-3-methyl-3,4-dihydrocoumarin 118b 
 
Methyl 3-[2-(benzyloxy)-5-chlorophenyl]-3-phthalimido-2-methylenepropanoate 117b (0.2 g, 
0.4 mmol) and pre-equilibrated 10% Pd/C catalyst (0.04 g) in absolute ethanol was hydrogenated 
at room temperature and atmospheric pressure. In a trial run, a very small quantity of the product 
was formed but in subsequent trials the desired product failed to form.  
6-Chloro-3-(chloromethyl)coumarin 121 
 
Conc. HCl (2.0 mL) was added to a solution of methyl 3-(2-benzyloxy-5-chlorophenyl)-3-
hydroxy-2-methylenepropanoate 106b (0.10, g, 0.2 mmol) in a mixture of AcOH (1.0 mL) and 
Ac2O (1.0 mL). The mixture was boiled under reflux for 2h, allowed to cool to room temperature 
and then poured into ice-cooled water (5 mL). It was then stirred for ca. 30 min and the 
precipitate which formed was filtered off and washed with hexane to yield 6-chloro-3-
(chloromethyl)coumarin 121 as a white solid (0.11 g, 80%), m.p. 100-102 oC (lit.134 111-114 oC); 
ʋmax/cm-1 1728 (C=O); δH (600 MHz; CDCl3) 4.55 (2H, s, 1`-CH2), 7.30 (1H, d, J = 8.7, ArH), 
7.48-7.54 (2H, m, ArH) and 7.82 (1H, s, 4-H); δC (150 MHz; CDCl3) 40.8 (C-1`), 118.1, 119.8, 
126.4, 127.3, 130.1, 131.9, 139.6 and 151.9 (Ar-C) and 159.4 (C=O). 
N-[(6-Chlorocoumarin-3-yl)methyl]phthalimide 124 
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6-Chloro-3-(chloromethyl)coumarin 121 (0.05 g, 0.22 mmol), was dissolved in CH3CN and to 
the solution was added potassium phthalimide (0.05 g, 0.27 mmol)  and the mixture stirred at 
room temperature for 2 days. The crude mixture was concentrated under vacuum and then water 
(3 mL) was added. The mixture was then filtered and the residue washed with water and dried 
yielding N-[(6-Chlorocoumarin-3-yl)methyl]phthalimide 124 as a white solid (0.06 g, 81%), m.p. 
238-240 oC (lit.122 206-208 oC; [HRMS: m/z calculated for C18H11ClNO4 (MH+) 340.0377. 
Found 340.0379]; ʋmax/cm-1 1702 (C=O); δH (400 MHz; CD2Cl2) 4.77 (2H, s, NCH2), 7.29 (1H, 
d, J = 8.8 Hz, ArH), 7.42-7.51 (3H, m, ArH), 7.79 (2H, s, ArH) and 7.90 (2H, s, ArH); δC (100 
MHz; CD2Cl2) 37.5 (NCH2), 118.3, 120.3, 123.8, 125.1, 127.4, 129.4, 131.8, 132.3, 134.7, 138.5 
and 152.1 (Ar-C), 160.0 and 168.0 (C=O). 
 
3.5. CUSTOMISED BAYLIS-HILLMAN CATALYSTS 
N-[3-(1H-Imidazol-1-yl)propyl]-D-camphor-10=sulfonamide 129a 
 
A solution of camphor-10-sulfonyl chloride (2.5 g, 10 mmol), in dichloromethane (3 mL) was 
added dropwise to a stirred solution of 1-(3-aminopropyl)imidazole (1.2  mL, 10 mmol) and 
triethylamine (1.6 mL, 12 mmol) at 0 oC. After 20 minutes, the mixture was allowed to warm up 
to room temperature and then stirred for 6 hours. The resulting mixture was filtered to remove 
the precipitated salt; water (10 mL) was added to the filtrate and the organic layer extracted with 
dichloromethane (3 x 4 mL). The organic layer was washed with brine, dried with anhydrous 
magnesium sulfate and then concentrated under vacuum to produce a cream crystalline solid the 
D-camphor-10-sulfonamide derivative 129a (2.49 g, 74%), m.p. 108-112 oC; [HRMS: m/z 
calculated for C16H26N3O3S (MH+) 340.1695. Found 340.1692]; ʋmax/cm-1 1742 (C=O); δH (600 
MHz; CDCl3) 0.86 and 0.99 (6H, 2 x s, 8- and 9-Me), 1.38-2.40 (9H, series of multiplets, 3-, 5-, 
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6- and 12-CH2 and 4-H) 2.88 and 3.34 (2H, 2 x d, J = 15.1 Hz, 10-CH2), 3.13 (2H, t, J = 5.8 Hz, 
13-CH2), 4.08 (2H, t, J = 4.0 Hz, 11-CH2), 6.09 (IH, d, J = 6.4 Hz, NH), 6.95, 7.02 and 7.57 (3H, 
3 x s, Ar-H); δC (150 MHz; CDCl3) 19.4 and 19.8 (C-8 and C-9), 26.3 and 26.9 (C-5 and C-6) 
31.5 (C-12), 40.2 (C-13), 42.6 (C-4), 42.9 (C-3), 43.8 (C-11), 48.7 (C-7), 49.1 (C-10), 59.0 (C-
1), 119.0 (C-14), 128.9 (C-15), 137.2 (C-16) and 217.0 (C-2, C=O). 
N-[3-(1H-Imidazol-1-yl)propyl]-(1S)-exo-borneol-10-sulfonamide 127a 
  
A solution of the camphor-10-sulphonamide 129a (0.5 g, 1.5 mmol) in ethanol (2 mL) was added 
dropwise to a stirred solution of NaBH4 (0.1 g, 2.7 mmol) in ethanol (4 mL) at 0 oC over 20 
minutes. The mixture was allowed to warm to room temperature and stirred for 8 hours. Water 
(10 mL) was added and the organic layer extracted with dichloromethane (4 x 3 mL), washed 
with brine, filtered and concentrated under vacuum to produce the bornyl sulfonamide derivative 
as a colourless oil 127a (0.49 g, 98%); [HMRS: m/z calculated for C16H28N3O3S (MH+) 
342.1851. Found 342.1849]; ʋmax/cm-1 3550 (N-H); δH (600 MHz; CDCl3) 0.80 and 1.04 (6H, 2 x 
s, 8- and 9-Me), 1.40-2.10 (9H, series of multiplets, 3-, 5-, 6- and 12-CH2 and 4-H) 2.84 and 3.40 
(2H, 2 x d, J = 13.7 Hz, 10-CH2), 3.10 (2H, t, J = 5.8 Hz, 13-CH2), 3.70 (1H, q, J = 7.0 Hz, 2-H), 
4.08 (2H, t, J = 6.8 Hz, 11-CH2), 6.31 (IH, s, NH), 6.93, 7.03 and 7.48 (3H, 3 x s, Ar-H); δC (150 
MHz; CDCL3) 19.9 and 20.5 (C-8 and C-9), 27.3 and 30.5 (C-5 and C-6) 31.7 (C-12), 39.1 (C-
13), 39.8 (C-11), 43.6 (C-3), 44.3 (C-4), 48.7 (C-7), 50.3 (C-1), 51.8 (C-10), 76.3 (C-2,C-OH), 
118.9 (C-14), 129.4 (C-15) and 137.3 (C-16). 
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N-(2-Pyridylmethyl)-D-campor-10-sulfonamide 129b 
  
A solution of camphor-10-sulfonyl chloride (1.25 g, 5 mmol), in dichloromethane (3 mL) was 
added dropwise to a stirred solution of 2-picolyamine (0.52  mL, 5 mmol) and triethylamine (0.8 
mL, 6 mmol) at 0 oC. After 20 minutes, the mixture was allowed to warm up to room 
temperature and then stirred for 6 hours. The resulting mixture was filtered to remove the 
precipitated salt. Water (10 mL) was added to the filtrate and the organic layer extracted with 
dichloromethane (3 x 4 mL). The organic layer was washed with brine, dried with anhydrous 
magnesium sulfate and then concentrated under vacuum to produce N-(2-Pyridylmethyl)-D-
campor-10-sulfonamide 129b as a brown oil (1.44 g, 89%); [HMRS: m/z calculated for 
C16H23N2O3S (MH+) 323.1429. Found 323.1430]; ʋmax/cm-1 1740 (C=O); δH (400 MHz; CDCl3)  
0.82 and 0.99 (6H, 2 x s, 8- and 9-Me), 1.38-2.40 (9H, series of multiplets, 3-, 5-, 6- and 11-CH2 
and 4-H) 2.91 and 3.46 (2H, 2 x d, J = 15.1 Hz, 10-CH2), 4.47 (2H, q, J = 3.0 and 3.8 Hz, 11-
CH2), 6.29 (1H, t, J = 5.9 Hz, NH), 7.17 (1H, dt, J = 4.1 and 8.5 Hz, ArH) 7.36 (1H, d, J = 7.7 
Hz, ArH) 7.66 (1H, td, J = 1.9 and 7.66 Hz, ArH) and 8.50 (1H, d, J = 5.2 Hz, ArH); δC (100 
MHz; CDCl3) 19.5 and 19.8 (C-8 and C-9), 26.2 and 26.9 (C-5 and C-6) 42.6 (C-4), 42.7 (C-3), 
48.3 (C-11), 48.5 (C-7), 50.0 (C-10), 59.0 (C-1), 122.0 (C-13), 122.5 (C-14), 136.8 (C-15), 149.1 
(C-16), 156.1 (C-12)  and 216.2 (C-2, C=O). 
N-Pyridin-2-ylmethyl)-(1S)-exo-borneol-10-sulfonamide 127b 
 
A solution of the camphor-10-sulfonamide 129b (0.48 g, 1.5 mmol) in ethanol (2 mL) was added 
dropwise to a stirred solution of NaBH4 (0.1 g, 2.7 mmol) in ethanol (4 mL) at 0 oC over 20 
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minutes. The mixture was allowed to warm to room temperature and stirred for 8 hours. Water 
(10 mL) was added and the organic layer extracted with dichloromethane (4 x 3 mL), washed 
with brine, filtered and concentrated under vacuum to produce, as a colourless oil, the borneol-
10-sulfonamide 127b (0.45g, 92%); ʋmax/cm-1 3560 (C=O); δH (400 MHz; CDCl3)  0.74 and 0.99 
(6H, 2 x s, 8- and 9-Me), 1.04-2.00 (9H, series of multiplets, 3-, 5-, 6- and 11-CH2 and 4-H) 2.81 
and 3.42 (2H, 2 x d, J = 13.9 Hz, 10-CH2),  4.07 (1H, dd, J = 4.1 and 8.1 Hz, 2-H), 4.44 (2H, dd, 
J = 2.5 and 7.4 Hz, 11-CH2), 5.29 (IH, s, NH), 7.23-7.32 (2H, m, ArH) 7.70 (1H, td, J =1.8 and  
7.7 Hz, ArH) and 8.55 (1H, t, J = 5.0 Hz, ArH); δC (100 MHz; CDCl3) 19.8 and 20.5 (C-8 and C-
9), 27.3 and 30.3 (C-5 and C-6) 39.2 (C-4), 44.3 (C-3), 47.8 (C-11), 48.7 (C-7), 50.3 (C-1), 52.3 
(C-10), 76.0 (C-2), 122.2 (C-13), 122.9 (C-14), 137.2 (C-15), 149.2 (C-16) and 155.3 (C-12). 
N-(1H-imidazol-2-yl)-D-camhor-10-sulfonamide 129c 
  
A solution of camphor-10-sulfonyl chloride (2.5 g, 10 mmol), in acetonitrile (25 mL) was added 
dropwise under nitrogen to a stirred solution of 2-aminoimidazole sulfate (2.6 g, 10 mmol) and 
KOH (1.2 g, 20 mmol), DMAP (0.24 g, 2 mmol) in acetonitrile (25 mL) at 0 oC and the solution 
was stirred for 1 hr. Water (12.5 mL) was then added and the resulting mixture extracted with 
EtOAc (2 x 30 mL). The organic layer was dried over MgSO4 and the solvent removed under 
vacuum to produce, as a brown oil, the camphor-10-sulfonamide 129c (1.9 g, 64%); [HMRS: m/z 
calculated for C13H20N3O3S (MH+) 298.1225. Found 298.1224]; ʋmax/cm-1 1741 (C=O); δH (600 
MHz; CDCl3) 0.83 and 1.10 (6H, 2 x s, 8- and 9-Me), 1.38-3.40 (9H, series of multiplets, 3-, 5-, 
6- and 10-CH2 and 4-H), 6.77 (2H, d, J = 3.8 Hz, ArH); δC (150 MHz; CDCl3) 20.1 and 20.3 (C-
8 and C-9), 25.7 and 27.8 (C-5 and C-6) 43.6 (C-3), 44.0 (C-4), 48.3 (C-10), 48.9 (C-7), 59.5 (C-
1), 114.1 (C-12 and 13), 148.8 (C-11) and 218.4 (C-2, C=O).  
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